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Abstract 
 
A pilot study to assess the feasibility of using the 
Travalert
®
 dosing aid to measure adherence 
 
Heidi Cate, 2011 
 
Glaucoma is a chronic condition, leading to progressive visual field loss and 
eventual blindness if left untreated.  With adequate medical therapy, 
progression of the disease can be reduced.  Non-adherence to glaucoma 
medication is a significant issue requiring further research.  However, rigorous 
evidence for novel adherence interventions requires a valid and reliable 
measure of adherence.  A gold standard for measuring adherence to glaucoma 
therapy has yet to be established.  This study evaluated the Travalert® dosing 
aid (TDA) as an effective measure of adherence to travoprost.  
 
One hundred patients prescribed travoprost for glaucoma or ocular 
hypertension, were approached and stratified by phase of travoprost use: newly 
prescribed or follow-up.  At baseline, self-reported adherence to travoprost was 
obtained from follow-up participants using questionnaires (Morisky Medication 
Adherence Scale and Frequency of Missed Dose).  All participants were given a 
TDA and daily adherence data were collected for 2 months.  Self-reported 
adherence was obtained from both newly prescribed and follow-up participants. 
Satisfaction with information received about travoprost was assessed using the 
Satisfaction with Information about Medications Scale questionnaire.  
 
The results suggested that future adherence studies should monitor adherence 
in excess of 100 days to overcome initial monitoring effects.  Furthermore, the 
use of intraocular pressure as a short-term clinical outcome measure to assess 
adherence to glaucoma medication was found to be unreliable and thus 
requires further investigation.   
 
This study has provided preliminary evidence that the TDA does not 
significantly alter patient eye drop use behaviour.  It has been demonstrated as 
a feasible, objective adherence measure revealing that 40.9% of participants 
deviated from their prescribed treatment regimen.  A further application of the 
TDA could be investigation of patient medication usage patterns to advance 
understanding of the complex area of non-adherence to glaucoma medication 
and aid the design of future adherence interventions. 
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1 Introduction 
 
Glaucoma is a significant contributor to vision loss throughout the world with 
more than 70 million people affected worldwide (1).  Studies have shown that 
about half of all glaucoma cases remain undiagnosed in the Western developed 
countries (2), the prevalence of this disease appears set to rise.  Furthermore, 
sight loss resulting from glaucoma causes problems with everyday activities and 
lifestyle; such problems can also have prominent psychological effects for those 
who suffer from the disease (3, 4). Glaucoma has thus been described as „an 
important global public health concern…ever increasing due to the rapidly aging 
population‟ (5).  
 
Glaucoma is a disease of the optic nerve, which can be classified into two 
different types each with specific risk factors and therapeutic treatments; 
primary open angle glaucoma (POAG) and primary angle closure glaucoma 
(PACG).  In PACG the iris blocks the drainage angle in the eye preventing the 
fluid (aqueous) draining from the eye.  The increased aqueous in turn increases 
the intraocular pressure (IOP), potentially causing permanent damage to the 
optic nerve.  Without medical intervention this can lead to a chronic and slowly 
progressive disease.  However, in some cases the drainage angle can become 
completely closed, in an acute manner, which causes a sudden elevation of IOP 
resulting in associated pain and visual loss requiring urgent medical attention.  
Conversely, POAG is always chronic and slowly progressive in nature with no 
warning signs of the permanent loss of vision that can be occurring.  The 
drainage angle remains grossly unaffected in POAG, but it is due to 
compromised drainage of the aqueous within the eye that causes elevation of 
IOP, or changes in IOP, which causes damage to the optic nerve.  Currently 
available treatment for glaucoma is aimed at reducing IOP by inhibiting the 
production and/or increasing drainage of the aqueous. 
 
There are fundamental risk factors that link race with both the prevalence and 
type of glaucoma, and associated severity.  For example, the rate of blindness 
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is higher in those of black race than white, and generally believed to be 
unrelated to socio-economic factors (6) (which are thought to exist when 
comparing black and white populations). Ethnic origin can play a role with 
respect to glaucoma risk and PACG, for example, is relatively less common 
compared with POAG in European regions but is more prevalent in Asia where 
it is almost equal to that of POAG (7). An anatomical precursor of PACG is a 
shallow anterior chamber, which can create a predisposition to PACG, this 
being more prevalent in Asia.  Surveys also suggest that a greater proportion of 
people affected by PACG are bilaterally blind (10% of POAG and 25% of 
PACG) (8).  
 
The most significant risk factor for glaucoma blindness is advanced loss of 
vision when the condition is first detected (9).  Thus it is essential to detect 
glaucoma early to prevent significant sight loss.  POAG is particularly difficult to 
detect and treat due to its slow progressive nature, with no patient symptoms 
until significant damage has occurred, and as such, for all the types of 
glaucoma, POAG holds a particular challenge for clinicians in terms of 
diagnosis, treatment and patient education.   
 
 
1.1  Primary open angle glaucoma  
Primary open angle glaucoma is characterised by progressive loss of retinal 
ganglion cells, reduction of retinal nerve fibre layer thickness and characteristic 
thinning of the neuroretinal rim at the optic nerve head (figure 1.1a and 1.1b) 
(10).  No single factor has been identified to cause POAG.  The damage done 
to the optic nerve is triggered in most cases by excessive pressure on the optic 
nerve that, over time, causes damage. The pressure is exerted by an increase 
of aqueous production (a watery liquid that fills the space between the lens and 
the cornea).   POAG is usually bilateral, but often asymmetric. Although often 
asymptomatic at presentation, untreated POAG results in characteristic visual 
field loss (usually peripheral) and later in the disease, this can even affect 
central vision.  In the UK, total blindness from glaucoma is uncommon, but it 
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remains the most common reason for an individual being registered blind in 
England and Wales, and the leading cause of irreversible, but preventable, 
blindness in the UK (11).  
 
Adapted from A.D.A.M (12) 
 
 
 
 
 
 
 
 
 
 
 
 
Artwork by Tarrant T.R. (13) 
 
Figure 1.1b  Front view of optic nerve head showing progressive 
glaucomatous optic nerve damage  
Normal optic nerve 
Severe glaucoma 
Moderate glaucoma 
Lens 
Cornea 
Figure 1.1a Cross section of the eye showing pressure on the 
optic nerve head. 
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1.2  Diagnosis 
The visual field test remains the most important functional test for assessing 
glaucoma.  Visual field testing is aimed at detecting any loss of visual field 
(peripheral and central) and provides a map of that loss which is helpful in the 
diagnosis and future monitoring of disease progression.  With automated 
Humphrey visual field analyses, the darker areas or black areas of the visual 
field print-outs indicate the areas of vision that have lost sensitivity to light 
relative to age-matched normal control eyes.  An example of a Humphrey visual 
field print-out can be seen in figure 1.2a.  Figure 1.2b shows how damage to the 
optic nerve seen by slit-lamp examination directly correlates to a loss of visual 
field shown on a visual field test as a black „arc‟.  However, not all optic nerve 
damage will be detected using a visual field test and thus optic nerve 
assessment using slit-lamp biomicroscopy or imaging is essential.  
 
The relative risk for POAG appears to rise continuously with the level of IOP 
and there is no evidence of a threshold IOP for the onset of the condition (14).  
Despite previous beliefs, elevated pressure is not always apparent in eyes with 
manifest glaucoma and thus an eye with an IOP lower than the mean for the 
population (15.5mmHg) may still show evidence of glaucomatous damage.   
The damage 
b. Photograph of optic disc The effect 
a. Visual field test results 
Figure 1.2 An illustration of nerve damage and corresponding visual field 
loss for the left eye of a POAG patient.  a. Visual field test results showing 
the visual field loss ‘arc’ and b. photograph of the optic nerve head 
showing the point of nerve damage  
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POAG has been subdivided into high pressure and normal pressure categories 
to reflect the fact that elevation of IOP is not always a feature of POAG.  The 
benefits of lowering IOP, even if the pressure is within normal limits at the time 
of diagnosis, have been proven (15).  The main risk factors for POAG are age, 
level of IOP, African descent and family history (6, 16).  It has also been 
suggested that diabetes, hypertension and migraine are associated risk 
factors(17).  
 
Normal tension glaucoma (NTG) is now considered to be a sub-group of POAG.  
Glaucomatous damage is detected whilst the mean diurnal IOP remains within 
the normal range (rarely above 21 mmHg, taken to be the statistical upper limit 
of the normal range) (18), thus making elevated IOP a significant risk factor, but 
not the only causal factor of glaucoma.  Evidence suggests that fluctuation of 
IOP plays an important role in the progression of optic neuropathy (19).  Drance 
(20) was one of the first to study diurnal IOP variation in patients with glaucoma.  
Drance pointed out that a single pressure reading on a patient may not 
necessarily be representative of what the pressure is most of the time, and 
certainly not indicative of highest value during the day (21).  However, finding 
the true diurnal and nocturnal IOP variation is problematic, the influence of body 
position on IOP over a 24-hour period and practicalities for the patient, all 
hindering assessment.  Thus, the available evidence for the role of fluctuation in 
IOP in the progression of glaucoma is controversial (19).  
 
For the purposes of further discussion, glaucoma refers to both POAG and 
NTG.  Although glaucoma is not currently curable, with early detection and 
appropriate therapy the majority of glaucoma damage is preventable and those 
diagnosed can expect to retain vision for the duration of their lives. 
  
   
17 
 
1.3  Ocular hypertension  
Patients with an elevated IOP without detectable glaucomatous damage on 
standard clinical tests have ocular hypertension (OH).  The treatment of OH is 
problematic, since although a risk factor for glaucoma, only a minority of 
patients from this group will actually develop glaucomatous damage.  Patients 
with mild/moderate OH can be left without treatment until the detection of early 
glaucomatous damage occurs (16).  It is reasoned that observation still allows 
timely intervention if damage begins before visual loss of consequence to the 
patient occurs.  Conversely, it is argued that up to 20-50% of optic nerve fibres 
may be lost focally before damage is recognised by conventional perimetry and 
that once damage occurs this makes the remaining optic nerve fibres more 
susceptible to further damage (16).  The current recommendation from the 
National Institute for Clinical Excellence (NICE) is to ensure that patients with 
significant risk of developing POAG should have treatment initiated before 
visual loss occurs.  However, patients with low risk of developing POAG should 
not be given unnecessary long-term therapy (18).  Much research and debate 
continues in unravelling the complexity of detecting and treating glaucoma and 
its risk factors appropriately.   
 
 
1.4  Treatment goals for glaucoma and ocular hypertension 
Treatment in its many forms, aims to decrease aqueous production and/or 
increase aqueous outflow to lower IOP and iron out the fluctuations in IOP over 
a 24-hour period.  The general therapeutic goal is a reduction in intraocular 
pressure by 20% - 30% from the initial pressure at which damage occurs and 
below 21 mmHg for cases of OH (15, 18).  Studies have shown that adherence 
to treatment regimens that achieve this IOP reduction may play a role in halting 
the progression for visual field loss in glaucoma (22) (14).  The Early Manifest 
Glaucoma Treatment Study randomised POAG patients (n=255) to treatment 
(argon laser trabeculoplasty plus topical betaxolol; n=129) or no treatment 
(controls, n=126) and these patients were followed-up every 3 months for 6 
years. The magnitude of initial IOP reduction was a major factor that influenced 
   
18 
 
outcome, but each 1mmHg rise of IOP at follow-up was associated with an 
approximate 10% increased risk of progression (14).  
 
In addition to this, consideration to the reduction of IOP fluctuation must be 
given particularly in the case of NTG patients.  Case studies have shown where 
a 30% reduction in IOP has been achieved but the magnitude of fluctuation 
remains unchanged, glaucomatous progression has been detected (19).   
 
Choice of treatment is made on an individual patient basis.  Consideration is 
given to the perceived threat to sight during lifetime, status of the fellow eye, 
adherence to treatment, the likelihood of surgical success and patient 
preferences regarding treatment options (18).  Many patients with early 
glaucomatous visual field loss and/or disc damage may not require treatment 
until progressive disease has been identified, although at present it remains 
impossible to accurately predict which patients will have significant progressive 
disease and which will have relative stability at any one time point.  
 
Target IOP is an estimate of the IOP below which the IOP should be maintained 
to prevent progressive loss of vision.  Numerous factors are considered in 
making the estimate of target IOP, including initial peak/mean IOP, degree of 
visual field loss, amount of optic nerve damage, age, gender and past/present 
medical history (18).  Frequent follow-up is required to ensure that target eye 
pressure is maintained and the risk of progressive field loss minimised.  At 
follow-up visits patients need assessment of IOP, visual fields and optic nerves. 
If target IOP is achieved but progression continues, further pressure lowering 
intervention is warranted and a new target IOP should be set (19). 
 
 
1.5  Treatment options 
Topical ocular hypotensive medications are a common choice for initial therapy 
and there are various types, which can be used alone or in combination.  Other 
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options include laser and filtration surgery techniques that can be employed to 
lower IOP by increasing aqueous outflow.  Currently, lowering IOP is the only 
proven form of management for preserving vision in eyes with glaucoma, 
although there is current interest in developing neuroprotective agents and 
drugs that improve ocular blood flow (which may aid optic nerve function) (17). 
 
1.5.1  Medical therapy 
There are many factors to consider when prescribing eye drops.  There are 
several medical contraindications to the use of certain medications such beta-
blockers (eg broncho-pulmonary disease or cardiac arrhythmia) since systemic 
absorption of beta-blocker drugs may cause adverse effects.  Further aspects 
include cost and quality of life balance, whether the patient has the manual 
dexterity required to administer the drops to one or both eyes (glaucoma 
manifestation and progression is not always symmetrical between eyes).  
 
There is a wide choice of topical agents available for treating glaucoma.  
Current ocular hypotensive agents in common use include prostaglandin 
analogues, beta-blockers, alpha-agonists, and carbonic anhydrase inhibitors.  
Prostaglandin analogues are often used as first line therapy and if only partly 
efficacious additional therapies are added to the therapeutic regimen.  When 
initial or additional therapies are not effective or side effects are experienced, 
alternative medications can be tried.  Effective therapy regimens are pursued 
until the „target pressure‟ is reached and the rate of progression is under 
control.  Thereafter, patients are reviewed, often on an annual basis, for the 
duration of their lives to ensure the „target pressure‟ is controlling progression 
with review of the treatment regimen at each follow-up visit (18).   
 
Medical therapy is the main form of treatment for glaucoma and thus adherence 
with glaucoma medication is an important factor in the control of glaucoma.  The 
level of adherence required should be expressed in relation to the clinical 
outcome to determine its clinical relevance (23).  An 80% adherence rate is 
widely quoted as acceptable for many systemic medications (24).  However, the 
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desired adherence rate for topical glaucoma medication has yet to be 
quantified.  The reasons for failure to establish a desired adherence rate for 
ocular hypotensive therapy include the inconsistency between patients in 
achieving their target IOP measure, the variance of drop efficacy between 
patients and the different treatment regimens used to control glaucoma on an 
individual basis.  Without supporting evidence to suggest otherwise, 
ophthalmologists at the Norfolk & Norwich University Hospital aim for 100% 
adherence for their patients.  Knowing that ocular hypotensive agents not only 
lower mean IOP, but also iron out IOP fluctuations, only strengthens the 
perceived requirement for 100% adherence.  Patients who stop and start 
treatment on a regular basis are thought to increase IOP fluctuation; on 
adherent days the IOP will be lower, on non-adherent days the IOP with be 
higher, causing peaks and troughs in IOP.  The non-adherent patient may thus 
inadvertently increase the risk of developing progressive glaucomatous visual 
loss.  However, the complexity and ethical implications associated with such a 
theory prevents the collection of empirical evidence.    
 
1.5.2  Laser therapy 
When there is a failure of medical therapy (effect or adherence related) laser or 
surgical management may be indicated.  Occasionally laser or surgical 
management is utilised as a primary option.  There are several types of laser 
therapy, including Argon Laser Trabeculoplasty (ALT), Selective Laser 
Trabeculoplasty (SLT) and cyclodiode laser therapy.  ALT improves the 
drainage of the aqueous fluid (the exact mode of action remaining unknown). 
SLT is a relatively new technology that uses laser to target specific cells within 
the trabecular meshwork as in ALT but it creates less thermal damage than 
ALT.  As a new therapy the long-term outcomes of SLT have not yet been 
determined.  However, it is thought that since SLT uses low power and causes 
less damage to the trabecular meshwork than ALT, the former is safer to repeat 
than the latter should the effects of the original treatment begin to wear off (25).  
Cyclodiode laser reduces the production of the aqueous fluid by partial 
destruction of the ciliary processes (part of the ciliary body that produces 
aqueous humour).  Cyclodiode laser, because of its destructive nature, is 
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generally reserved for treatment of severe glaucoma where all other therapies 
have failed, although the threshold for using cyclodiode laser is falling as 
clinicians become more familiar with it.  Cyclodiode is often used when an eye 
has become blind but because of elevated pressure remains painful.   
 
1.5.3  Surgical therapy 
The generally accepted gold standard surgical technique used in the 
management of POAG is a form of glaucoma filtration surgery called 
Trabeculectomy.  Trabeculectomy is generally very effective in achieving low 
IOPs but, as with all surgery, carries the risk of complications, failure and 
potentially total loss of vision should there be significant haemorrhage or 
infection associated with the surgery.  Figure 1.3 shows a simplified step-by-
step diagram of the procedure.  The procedure site is just above the iris through 
the sclera as shown in figure 1.1.  A partial thickness scleral flap is formed, 
which is sewn loosely back in place overlying a small penetration into the 
anterior chamber.  In successful cases, the fistula between the anterior 
chamber and the sub-conjunctival space allows continual outflow of aqueous 
through the created opening.  In the early days following surgery, the flap can 
be adjusted to achieve the right amount of aqueous outflow to try and achieve 
optimal IOP.  Post-operatively the continual effectiveness of the procedure must 
be monitored to ensure that the IOP remains low and the features of glaucoma 
stable.  Supplementary eye drops can be used to lower IOP further if IOP starts 
to rise or progression of the glaucoma occurs and the surgery appears to be 
only a partial success.  Other surgical procedures can be performed to lower 
IOP and these include non-penetrating filtration surgery or the insertion of 
drainage tube devices. 
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Artwork by Tarrant T.R. (26) 
Figure 1.3 Diagram of trabeculectomy procedure 
 
 
1.6  Measuring rate of progression 
Glaucoma is usually a slowly progressive disease with the finality of blindness 
typically taking decades.  In spite of treatment, most glaucoma will continue to 
progress (18), albeit in a minor way when IOP is adequately controlled. 
Measures of progression are essential to ensure that the treatment reduced IOP 
is achieving the goal of reducing the damage to the optic nerve.  Progression 
may be considered to have occurred when there is evidence that visual field or 
optic disc damage has worsened (18).  As more technology becomes available 
more sensitive and measurable progression markers have been established to 
assess optic disc appearance and visual field sensitivity.  
 
There have been several large scale glaucoma studies looking at the efficacy of 
medical treatment in delaying or preventing the onset of POAG.  The Ocular 
Hypertension Treatment Study (OHTS; n=1636) randomised patients with OH 
(with no evidence of glaucomatous damage) to observation or treatment (topical 
ocular hypertensive medication).  The primary outcome was the development of 
a visual field defect or optic disc deterioration attributed to conversion from OH 
to POAG.  The OHTS study demonstrated that the probability of developing 
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glaucoma over a 6 year period was reduced from 9.5% to 4.4% with medication 
(hazard ratio, 0.4; 95% confidence interval, 0.27-0.59; p<0.0001).  Therefore, 
maintaining IOP at a desirable range was effective in delaying the onset of 
POAG in patients with elevated IOP and thus an effective means of reducing 
glaucomatous progression (27). 
 
Other studies have found that patients with normal tension glaucoma, a 
reduction in IOP from 16 mmHg to 11 mmHg resulted in a reduction risk of 
progression from 60% to 20% (Collaborative Normal Tension Glaucoma 
Study)(28).  In the Advanced Glaucoma Intervention Study, patients with POAG 
and moderate to severe visual field loss with low IOP below 18 mmHg, no net 
progression of visual field loss was noted during 8 years of follow-up (29).  The 
results of the OHTS, CNTGS and AGIS studies have demonstrated the 
importnace for long-term follow-up of glaucoma and OH patients to ensure that 
target IOP is maintained and this pressure has controlled the progression of 
optic nerve damage and/or visual field defects.   
 
There is a clear association between adequate IOP control and patient health 
outcome.  Given that current medical treatment to achieve IOP control requires 
daily dosing, adherence to such therapy is paramount.  Patients not adherent 
with their prescribed medical regimen risk the reduction of their remaining eye-
sight and eventual blindness.   
 
 
1.7  Adherence  
The language used to describe patient medication-taking behaviour has evolved 
with time. There are many different terms used to describe adherence, often 
interchangeably, including compliance, adherence, and concordance.  Each has 
a different connotation and subtleties that need further explanation.  
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Traditionally practitioners have used the term „compliance‟ to describe the 
extent of conformity to treatment regimens with respect to timing, dosage and 
frequency.  Use of the term „compliance‟ has become strongly criticised since it 
is thought to imply a negative image relationship between the prescriber as “the 
instructor” and patient as “follower of doctors orders”.  In view of this, the term 
„adherence‟ has been favoured as recognising a patient‟s right to choose and 
remove the concept of blame when non-adherence ensues.  It accepts that the 
patient has a freedom to decide whether or not to adhere to the doctor‟s 
recommendations (30).  
 
The term „concordance‟ is used to describe the interaction between the 
prescriber and patient at the point of prescribing.  However, in recent years 
„concordance‟ has been used to describe the consultation process from the 
doctor and patient agreement on therapeutic decisions, to prescribing 
communication and patient support in taking medicine.  This recognises the 
need for patients and doctors to work together to reach agreement even when 
there may be conflicting views (30).  Whereas adherence refers to the extent of 
conforming to the recommendations in terms of timing, dosage and frequency, 
the term persistence describes the duration of medication use from initiation to 
discontinuation.  Thus, a patient remaining adherent to the dosing regimen in 
terms of dosing frequency but discontinues use of the treatment earlier than 
recommended, is adherent but not persistent. 
 
1.7.1  Magnitude 
Adherence does not just relate to taking medication but also to lifestyle and 
exercise regimens and dietary considerations in relation to health.  As such, 
The World Health Organisation (WHO) adherence project group have adopted 
their own definition of adherence: „the extent to which a person’s behaviour – 
taking medication, following a diet, and/ or executing lifestyle changes, 
corresponds with agreed recommendations from a health care provider’ (31).  In 
2003, the WHO project group found that poor adherence to treatment regimens 
was a commonly reported problem with an estimated 50% adherence rate for 
long term treatment of chronic illnesses in developed countries (31). 
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A meta-analysis of studies from 1948-1998 reporting adherence to medical 
treatment was published in 2004 by DiMatteo et al.  The average non-
adherence rate was 24.8%; adherence was highest in HIV disease, arthritis, 
gastrointestinal disorders or cancer and lowest in pulmonary disease, diabetes 
or sleep.  In chronic diseases such as hypertension or diabetes, medication 
adherence, at best, was thought to be estimated at 75% (32).  
 
Successful management of glaucoma relies on establishing effective IOP 
lowering medication regimens.  However, establishing efficacy is fraught with 
problems.  Winfield et al. found that, even if asked, 69% of patients taking 
glaucoma medication would not tell practitioners they were having problems 
with adherence and persistence, and approximately 50% of the individuals 
started on glaucoma medications have been reported to discontinue them within 
6 months (33).  It can, therefore, be difficult for clinicians to establish true 
efficacy of prescribed ocular hypotensive eye drops.  If a patient fails to respond 
to therapy, a change in therapy is often tried or additional topical agents added; 
this only leads to further adherence problems since adherence with therapy 
appears to decline with increasingly complex regimens (33).  
 
Previous glaucoma adherence studies have demonstrated high rates of non-
adherence.  Olthoff et al., through a systematic review of 34 literary articles, 
found that percentages of patients who deviated from their prescribed 
medication regimen ranged from 5 - 80% [20].  More recently, studies using the 
Travalert Dosing Aid®, an electronic eye drop monitoring device, have reported 
adherence rates in the order of 75% (34).  It is likely that the wide range in 
reported adherence rates is due to inconsistency in the definition of non-
adherence and differences in the methodology for assessing non-adherence 
(an issue discussed further in section 1.10).   
 
   
26 
 
Other factors affecting the studies reviewed by Olthoff et al. include a lack of 
adjustments made for confounding variables.  As an example, the study by 
Konstas et al. (35) used a cross-sectional assessment of patients using various 
eye drops for treatment of their glaucoma.  No adjustment was made for 
patients who were required to use eye drops more frequently or with more 
complicated dosing regimens, which has been reported to prohibit adherence.  
Length of adherence monitoring period, whether researchers were blind to the 
control and intervention groups, patients changing their adherence behaviour 
due to the fact they are being monitored (particularly just before clinic visits if 
IOP measure is the determinant of adherence), use of language in 
questionnaires which could introduce socially desirable answers and selection 
bias, are all areas for potential methodological failure.  Whilst lacking in good 
quality and quantity of adherence studies, it is not surprising that studies of 
comprehensive methodological design have been compared under one 
umbrella.  Ideally, only comparisons of studies using the same methodology 
should be used for this topic area because of the known complexity of 
adherence; only then will we begin to understand true trends and adherence 
rates to guide future research.   
 
Research has shown that even when patients do adhere to their medication 
regimen, drop application technique is poor.  Only 60% of patients instilled the 
correct number of drops in a study observing 140 experienced glaucoma 
patients (36).  The most commonly cited problems have been reported include 
difficulty or problems with: drop administration (44%), reading the print on the 
bottle (18%), side effects (16%), bottle squeezing (14%), seal removal (14%) 
and remembering to take medication (12%) (37).  A recent study carried out to 
evaluate techniques for instillation of eye drops in glaucoma patients found that 
nine out of ten glaucoma patients were not able to correctly instil eye drops into 
the eye.  Problems encountered included the wrong number of drops squeezed 
out from the bottle, eye drops falling on eyelids or cheek, the dropper tip 
touching the eye (38).  In addition it has been determined that 38% of patients 
reported not always administering their own eye-drops (33).  It is important, 
therefore, that family members, carers and friends of a significant proportion of 
patients with glaucoma are educated about proper drop administration.  
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1.7.2  Cost and health implications 
Once diagnosed, patients with glaucoma require lifelong control of IOP with 
careful monitoring of the optic disc and visual field; the costs associated with the 
management of such a disease are therefore high.  The annual economic 
burden of glaucoma in the UK was estimated at £62 million in direct medical 
costs in 1994 (39).  The Cost of Blindness Report in 2003 estimated that as a 
chronic illness, requiring life-long treatment and follow-up, an individual lifetime 
cost for a patient with glaucoma was as high as £40,000 in the UK at that time 
(40). 
 
Several studies have noted that the rate and extent of visual field loss are worse 
with higher mean and peak IOP measures (41, 42).  A study carried out by 
Stewart et al. in patients with advanced POAG (n=72) found a significantly 
lower mean (15.4 ± 2.7mmHg) and peak (24.5 ± 6.9mmHg) IOP in patients 
whose vision remained stable for five years (cf 21.3 ±3.2 and 39.2 ±11.0mmHg, 
mean and peak IOP respectively, for those with decreased vision; p<0.001)(43). 
Stewart et al. found that patients who lost visual function were significantly less 
adherent with medical and surgical recommendations in comparison with 
patients whose vision remained stable (p<0.001).  Glaucoma progression was 
seen in 50% of all patients noted to have poor adherence and remained stable 
in 90% of adherent patients.  However, the methodology for assessing 
adherence was not described by Stewart et al. (43).   
 
The evidence suggests that prevention of glaucoma is essential, having clear 
health and financial implications both for patient and society.  In a study to 
describe the patterns and economics of glaucoma treatment, published by 
Denis et al., 88 ophthalmologists examined 5 years of the medical item 
consumption data of 337 OH and POAG patients (44).  Lower costs were 
positively associated with patients with less visual field defects.  Higher 
expenses were always related to a greater severity of optic nerve damage and 
additional costs were always seen as the disease worsened.  It is accepted that 
non-adherence can be mistaken for low medical efficacy leading to 
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unnecessary additional prescribing or surgery.  Although Denis et al. did not 
carry out a cost analysis of poor adherence, the number of medical therapies 
tried contributed independently, in an additive way, to the total cost of glaucoma 
treatment in their study (44).  Non-adherence can be managed as treatment 
failure necessitating more frequent hospital appointments and/or diagnostic 
tests, this leading to increased healthcare expenditure.  Treatment failure can 
also result in changes to medication prescribed, wastage of unfinished 
pharmaceutical supplies or the costs of surgery that may have been 
unnecessary.  If surgical treatment is required, this not only increases the cost 
of glaucoma care significantly, but adds surgical risk to the patient (44).  The 
presence of glaucoma rather than OH has also been shown to increase 
healthcare costs (44) suggesting that early interventions in prevention of 
glaucoma are justified if cost and economic evaluation are to inform therapy 
decision making.  
 
 
1.8  The barriers to identifying non-adherence 
One of the major methodological problems highlighting the complexity of non-
adherence is the use of correct classification systems for the causes of non-
adherence. Tsai et al. created a four category classification of 71 identified 
barriers to adherence, naming regimen factors, individual patient factors, 
medical provider factors and situational (i.e. social/environmental) factors as 
significant obstacles to adherence (45). In addition, Olthoff et al., subdivided 
determinants of adherence into four groups to summarise the following findings:  
(1) Demographic / sociographic variables; age was found to have no relation to 
adherence, males were positively associated with non-adherence (though in 
most cases results were not significant) and there was a „probable‟ relationship 
between ethnic background and adherence (though this has not been uniformly 
investigated).  
(2) Knowledge, attitude and health-behaviour related variables; a link between 
knowledge of glaucoma and compliance was concluded to be inconsistent. 
However, „non-adherers‟ were considered to be less knowledgeable than 
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„adherers‟ when assessed on single items of knowledge rather than their 
general level of knowledge about glaucoma. 
(3) Aspects of disease; non-adherence was positively associated with better 
visual acuity.  No association was found between duration of glaucoma and 
non-adherence.   
(4) Aspects of treatment; non-adherence was found to be greater when regimes 
required more than two eye drops.  Complexity of regimen, whilst evident in 
three studies, was concluded as unlikely to affect adherence (23).  
 
It is unsurprising that complex interventions are most effective given the 
multifactorial nature of non-adherence.  A meta-analysis of psychosocial 
interventions to improve medication adherence across a range of conditions, 
demonstrated that adherence-enhancing interventions could improve 
medication-taking behaviour beyond the level achieved through standard 
patient education and medical care.  An average 35% decrease in non-
adherence was reported post intervention, with the best techniques producing a 
decrease of up to 44%.  The most effective interventions were multi-component 
and „personal‟ intervention methods (involving personal contact) rather than 
those that were purely „technological‟(46).  Multi-component adherence 
interventions however, have frequently lacked grounding in such theory, 
resulting in ineffective components and thus a less cost effective model.  It is 
therefore proposed that it is necessary to develop and trial an intervention that 
targets the factors elucidated in theoretical models to determine their impact on 
adherence.   
 
 
1.9  Behavioural Models 
The Health Belief Model (HBM) was first described in 1966 by Rosenstock (47) 
and this was summarised by Dunbar  et al. in 1979 (48).  The model states that 
health practitioner‟s directions will be followed providing the patient believes the 
following elements:   
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 they have susceptibility to the illness, 
 the consequences of such illness are serious,  
 the health practitioner‟s directions will be beneficial in reducing risk or 
severity of the disease,  
 the costs of the action do not exceed the benefits.  
The application of health promotion is key in this model for providing the patient 
with knowledge of their condition to enable them to recognise the importance of 
these elements. 
 
The HBM focuses on patient behaviour related to illness prevention but 
provides no explanation of medication use behaviour or to adherence for 
patients already suffering from a chronic illness.  However the theory of 
Reasoned Action addresses these issues and has been used to predict patient 
adherence. 
 
1.9.1  Theory of Reasoned Action and Theory of Planned Behaviour  
The Theory of Reasoned Action (TRA) is a general model of behaviour, which 
states that behaviour is determined by a person‟s intention to perform that 
behaviour (Figure 1.4).  The intention is governed by two factors; attitude 
toward the behaviour (beliefs about the outcomes of the behaviour and the 
value of these outcomes) and the influence of the social environment and 
subjective norm surrounding that person (beliefs about what other people think 
the person should do and motivation to comply with the opinions of others).  
The TRA suggests that in a healthcare setting, patients will evaluate the 
benefits and drawbacks or the barriers of adhering, which then forms their 
intentions and predicts their behaviour. 
   
31 
 
Adapted from Horne and Weinman (49)  
Figure 1.4  Theory of Reasoned Action (TRA) 
 
The Theory of Planned Behaviour (TPB) adds to TRA the concept of perceived 
control over the opportunities, resources and skills necessary to perform a 
particular behaviour and overcome the potential barriers.  In a healthcare 
setting TBP would relate to what a patient feels about the behaviour that is 
within their control, such as confidence in their own abilities.  Potential barriers 
might include manual dexterity and memory problems.  Figure 1.5 shows how 
these factors interlink with the TRA. 
 
The TBP suggests that the best predictor of medication-taking behaviour is 
intention; the strength of intention is determined by the attitude towards the 
behaviour, the subjective norm and perceived control, and can all be influenced 
by patient demographics.  Attitudes towards behaviour are formed from beliefs 
about the likely outcome of behaviour and value of that outcome.  The 
subjective norm is the standard at which the patient would like to be.  The 
subjective norm is formed by the patient‟s own beliefs regarding the views of 
others in relation to their behaviour and motivation to comply with the views of 
others.  Perceived control is formed from beliefs about the existence of barriers 
or facilitators of adherence and their relative strength. 
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.
 Adapted from Horne and Weinman (49) 
Figure 1.5  Theory of Planned Behaviour (TPB) 
 
A meta-analysis of research using TPB was carried out by Armitage et al., who 
reviewed a database of 185 studies published to the end of 1997 (50).  The 
TPB accounted for 27% and 39% of the variance in behaviour and intention, 
respectively using an objective measure.  When behaviour measures were self-
reports (a subjective measure), the TPB accounted for 11% more of the 
variance in behaviour than when behaviour measures were objective or 
observed.  The meta-analysis suggested that greater adherence could be 
achieved with TPB.  However, further work is needed to look at the 
methodological aspects of such research since the variance achieved relied 
upon self-report of medication-taking behaviour (50).  Evidence suggests that 
data from patient self-report could lack validity and reliability due to self-
presentational biases thought to be induced by this methodology (51).  Despite 
potential methodological biases, behavioural decision-making models such as 
the TRA and TPB have tended to rely on the data generated by self-reports; the 
threat to reliability of the model having, to some extent, been subsequently 
ignored. 
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1.9.2  Social cognitive theory  
The key constructs from social cognitive theory (SCT) are self-efficacy and 
outcome expectations.  The SCT implies that in order to achieve optimal 
adherence, the individual must believe in his or her capability to perform the 
appropriate behaviour.  Outcome expectations relate to whether the individual 
believes that certain behaviour will have a positive impact on a health condition.   
The person must value the outcomes or consequences that he or she believes 
will occur as a result of performing a specific behaviour or action.  Self-efficacy 
can be increased in many ways, for example, providing clear instructions and 
giving an opportunity for training and modelling the desired behaviour.  Using 
the theoretical framework of SCT, the implication is that if an individual believes 
that taking eye drops will help their glaucoma then that individual is more likely 
to administer their eye drops than someone who does not believe that they are 
helpful.  
 
A recent study carried out by Sleath et al. (n=191) developed two instruments to 
measure self-efficacy and outcome expectation in glaucoma patients using eye 
drops (52).  The self-efficacy scale was modelled on the medication self-efficacy 
scale in hypertensive patients scale because glaucoma was considered similar 
to hypertension with respect to the asymptomatic and chronic nature of both 
conditions.  The glaucoma outcome expectations instrument was modelled on 
an outcome expectations scale from asthma.  To assess validity, Sleath et al.  
distributed two self-report measures of adherence (the Morisky Medication 
Adherence Scale (53) and a visual analogue scale measure) to 60 glaucoma 
patients.  The self-efficacy scales used had a significant association with the 
patient self-report of adherence measures.  The six-item self-efficacy scale had 
a Cronbach α-coefficient of 0.87, with scores ranging from 7.91 to 18 indicating 
the scales were internally consistent.  Sleath et al. concluded that patients with 
higher self-efficacy were significantly more likely to be adherent with their 
glaucoma medications.  However, the outcome expectations scale did not 
correlate significantly with either adherence measure (52).  The self-efficacy 
and outcome expectations scales identified by Sleath et al. are important since 
they help to explain adherence behaviour and have the potential to be used in 
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clinical practice.  Patients could be screened to detect those who have low self-
efficacy or confidence in using their glaucoma medications so that providers 
could educate and attempt to improve self-efficacy and medication adherence 
for these individuals.   
 
 
1.10   Measuring adherence 
Research that aims to develop new adherence interventions or assess existing 
interventions for patients with glaucoma is problematic.  Olthoff et al. reviewed 
intervention protocols for glaucoma adherence studies and concluded that all 
studies reported a significant improvement in adherence (23).  However, they 
suggested that more work needed to be done in this area due to the majority of 
studies having poor research design.   Only the studies of Norell and Granstrom 
(54, 55) were considered by Olthoff et al. to be demonstrative of acceptable trial 
design due to their use of an objective outcome measure: a medication monitor 
recording the day and time of opening the bottle.  It is widely accepted that 
electronic monitoring is the „gold standard‟ measurement for assessing 
adherence (56).  
 
Review of the literature has revealed that it is the adherence measure itself that 
remains the obstruction to gathering good empirical evidence for adherence 
interventions.  Designing and implementing measures of adherence is fraught 
with difficulties and without the correct tools, researchers will never truly 
understand or be able to evaluate adherence interventions.  Furthermore, it is 
plausible that every health condition and the treatment options available for that 
condition will also carry their own set of measuring difficulties. 
 
Measures of adherence can be categorised as either objective or subjective and 
each have their advantages and disadvantages.  Whilst objective measures 
remain the gold standard of clinical trials they have several drawbacks.  
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1.10.1 Therapeutic outcome 
In some diseases, therapeutic outcome can be related to patient adherence 
such as in the case of epilepsy.  Objective observations can be made which are 
directly attributable to the medication.  Hypertension can be assessed by taking 
blood pressure readings and diabetes by glucose or HbA1 monitoring.  
 
The ultimate goal in the current management of glaucoma is the avoidance of 
progressive optic nerve damage and the associated deterioration in visual field.  
The chronic nature of the condition, however, means that determination of the 
effectiveness of therapy, or adherence to therapy, would require long term 
follow-up if such measures as optic nerve damage or visual field loss were to be 
used.  An alternative would be to measure IOP as an assessment of therapeutic 
efficacy and/or adherence.  However, when assessing outcomes for the 
effectiveness of ocular hypotensive medications used to treat glaucoma or OH, 
there is no universal standard to measure achieving IOP thresholds, IOP-
controlled days and percentage reduction from peak or mean IOP (57).  
 
There are several reasons as to why assessment of IOP control is problematic 
with respect to determining medication efficacy or adherence.  As previously 
discussed, it is well documented that IOP is not constant and varies 
considerably throughout the day, particularly in eyes with glaucoma.  Therefore, 
utilising IOP thresholds or IOP reduction by comparing one IOP measurement 
at a random time point against another is relatively futile with respect to 
assessing adherence.  Likewise, whatever the target IOP, there is no guarantee 
that apparent achievement of that target IOP will halt progression of the 
glaucoma due to the variation of individual progression rates, often determined 
by other IOP independent risk factors such as family history, co-morbidity and 
degree of glaucomatous damage already sustained. 
 
Strategies to accommodate diurnal IOP fluctuations include the use of multiple 
daily readings (peak, trough and calculation of a daily average), or integrating 
   
36 
 
IOP measures collected at several time points during the study period (as in the 
Ocular Hypertension Treatment Study (27)).  However, this methodology is 
timely and inconvenient and can also increase participant awareness that they 
are being monitored.  Adherence research is by its very nature difficult since 
simply trying to measure adherence will naturally encourage patients to adhere 
to their medication regimens.  Patient reactivity to improve or modify their 
behaviour simply in response to the fact that they are being studied is known as 
the Hawthorne effect, a well-documented effect for a variety of conditions (58).  
Making a distinction between real changes in adherence levels and 
experimental effects is difficult to achieve, but inclusion of a control group can 
help quantify experimental effects.  
 
There have been six studies that have assessed non-adherence in relation to 
IOP or the progression of visual field loss (35, 59-63).  A relationship would be 
expected because it is known that ocular hypotensive treatment is effective and 
adherence should result in a lower IOP.  However, only the study by Konstas et 
al. (35) found non-adherent patients to have a higher mean IOP than adherent 
patients (n=100) (22.9 vs 18.5 mmHg; p>0.001).  Adherence in this study was 
determined by patient self-report of missed doses per month and this correlated 
with level of IOP.  However, this was a study of relatively small sample size and 
it relied upon patient self-report of adherence, which is known to underestimate 
adherence.  
 
A failure to consistently demonstrate a relationship between adherence and IOP 
control (23), could be explained by the lack of a quantified correlation or that the 
methodological quality of the studies performed so far has been poor, but more 
likely that the complexities of assessing the level of IOP due to individual 
differences, different types of glaucoma and effect of the diurnal variance lead 
to „noisy data‟. 
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In summary, with so many variables to control, assessing adherence rates 
based on rate of glaucomatous progression or IOP control is neither 
straightforward nor practicable. 
 
1.10.2 Blood and serum samples  
Many reviews have suggested that biologic assays are the most accurate 
measure of patient non-adherence (64).  Any body fluid can be used for 
analysis to enable the concentration of the therapeutic drug to be measured.  
However, it is not always possible to detect the concentration of the therapeutic 
drug under investigation and therefore a marker drug, which has no therapeutic 
benefit other than its ability to be accurately assessed, can be formulated and 
used to assess adherence with the medication.  Such methodology, although 
objective, does have limitations.  Some drug concentrations are highly variable 
due to individual variability of absorption and elimination.  Development of 
pharmacokinetic models to support such methodology is costly and not always 
possible.  Assessment of drug concentration has not been used to assess 
adherence with ocular hypotensive medications. 
 
1.10.3 Prescription databases 
Prescription databases provide prescribing data that can be used to estimate 
the level of adherence based on how many new prescriptions have been used.  
However, while collection of a prescription shows intention to use medication, it 
does not ensure its use.   
 
Choo et al. in the United States, evaluated patient self- report, pharmacy 
dispensing records and pill counts using electronic monitoring as a validation 
standard for adherence with systemic antihypertensive treatment (65).  In the 
patients using antihypertensive‟s (n=286) it was revealed that refill prescription 
patterns were moderately correlated with electronic monitoring (refill adherence 
r=0.32) and it was suggested that pharmacy dispensing records could be used 
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with predictive validity; gaps in the medication supply suggesting possible non-
adherence (65).  
 
Prescription claims databases as described in the Choo et al. (65) study are 
particularly common place in the US as their healthcare system relies heavily 
upon insurance claims for healthcare costs.  Prescription claims data are 
particularly useful for identification of non-adherence due to discontinuation or 
changes in treatment.  However, if patients do not collect prescriptions from the 
same source each time or within the same pharmacy networks, the recording 
process can be unreliable (66).   
 
Consideration of inter-country healthcare systems are required as elements of 
cultural disparity and structural differences between healthcare systems can 
affect health beliefs and attitudes which may affect adherence.  Patients paying 
for medication may be less likely to adhere when a condition is asymptomatic 
(67).   
 
1.10.4 Electronic monitoring 
Electronic drug monitoring is one of the more reliable methods employed to 
measure adherence, especially when dealing with eye drops, since „pill counting 
methods‟ cannot be employed.  There is the potential that the practice will 
change patient behaviour because the monitoring is so obvious (Hawthorne 
effect).  However, a study carried out by Cramer et al. found that reactivity bias 
to medication monitoring devices was short lived and patients quickly return to 
their self-medication behaviour patterns (56).  
 
Both studies by Norell and Granstrom used electronic medication monitors to 
obtain an objective measure of adherence with topical ocular hypotensive 
medication (54, 55) and reported significantly improved adherence following 
additional education and tailoring programmes.  However, adherence was only 
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monitored using the devices for a 20-day period following the educational 
intervention.
  As suggested by Cramer et al. (56), the 20-day period may not 
have been a long enough period of monitoring to overcome the reactivity bias to 
the monitoring device itself and therefore longer term follow-up should have 
been used to allow patients to revert to their usual medication behaviour 
pattern.  Longer term follow-up studies are needed to determine how long 
improved adherence persists following an intervention, but the use of an 
electronic device to measure adherence would appear to be satisfactory and 
little else at present can compete. 
 
More recently, Alcon® has introduced the Travatan dosing aid (Travalert®,TDA) 
which electronically stores data on the time, date and number of drops 
administered.  The TDA can only be used in conjunction with (Travatan® 
(travoprost) and Duotrav® (travoprost/timolol combination) (manufactured by 
Alcon® eye drop due to aperture size restricting other and shaped bottles from 
fitting the aid.  Three studies using the TDA have reported that it accurately 
records drop administration (68-70). 
 
However, electronic bottle monitoring, pill counting or bottle weighing may also 
suggest to patients that they are not being trusted, resulting in resentment by 
the patient and a possible reduction in adherence or an undermining of any 
intervention itself (71).  Electronic devices are also expensive to fund, often 
more difficult to operate than the bottle itself, and thus lead to a predetermined 
selection of participants who would be able to operate such devices rather than 
being usable by the greater patient population. 
 
1.10.5 Physician estimated adherence 
It has been reported that ophthalmologists do a poor job of detecting non-
adherence in their patients (72).  In a study published in 1986, eye drop 
medication monitoring data was compared with ophthalmologist predictions of 
adherence (73) and it was found that ophthalmologists were unable to identify 
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which of their patients were adhering correctly to prescribed therapy.  More 
recently, in an observational cohort study using the TDA, (n= 196) virtually no 
correlation between physician predictions and of adherence and electronic 
monitor recordings (intraclass correlation coefficient, 0.09; 95% confidence 
interval, 0.00 – 0.19) was identified (70). 
  
Furthermore, a study of non-compliance to eye drops (33) found that 69% of 
patients interviewed would not tell a doctor of their problems using eye drops; 
this was reflected in the lack of awareness among the medical staff of the 
problems experienced by these patients.  This latter finding was echoed in a 
more recent study by Lacey et al., that examined the barriers to adherence, in 
which it was found that there was unsatisfactory hospital-led education where 
“doctors appeared too busy clinically to have time to provide adequate 
education … and poor communication” (67).  Thus, physician estimation of 
adherence is not a reliable measure of adherence.  
 
1.10.6 Self-report of adherence 
Patient self-report is used frequently as a measure of indirect adherence 
measurement.  It includes questionnaires, dairies and/or interviews.  The 
advantages of using self-report tools are that they are well-used, well-validated, 
generally cheap and simple to carry out and specific to non-adherence.  
However, it has been suggested that self-report measures can yield higher 
adherence estimates in comparison with objective measures (70).  The 
discrepancy between self-report and objective measures of adherence is 
attributed both to the social desirability to be adherent to medication regimens 
as prescribed by clinicians and memory bias; if non-adherence is due to 
forgetfulness, how can a missed dose be remembered for the purposes of self-
report?  In addition, if patients have misinterpreted their prescribed regimen, 
they may not realise that they are not adhering and therefore self-reported 
adherence at a given time is not necessarily representative of adherence over a 
period of time.   
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The visual analogue scale (VAS) is a commonly used picture-graphic tool used 
in questionnaires to assess subjective attitude to characteristics that cannot be 
measured, such as “how much pain do you feel”.  As a measure of adherence, 
patients are asked to put a line on the scale indicating how much of the time 
they consider that they use their medication as directed.  It has been proposed 
that VAS scales may be useful in assessing medication adherence in lower-
literacy populations (74).   
 
The missed-dose method for assessment of adherence is simple and 
straightforward and involves asking patients to confirm whether they ever miss 
taking their medications and if so how often they do: once a day, once a week, 
once a month, rarely, never (75).  The missed-dose method can also be used in 
open-ended face-to-face interviews leaving the patient free to quantify their 
level of adherence if no suggested time has been given.  The missed-dose 
technique for assessment of adherence has the advantage of acknowledging 
that many people have difficulties with taking medication, thus indicating it is 
acceptable to experience a degree of non-adherence.  For example, one could 
say to a patient “that people often have difficulty taking their medication for one 
reason or another and I am interested in finding out any problems that occur so 
that I can understand them better”.   
 
A recent glaucoma adherence study reported by Ajit et al (34) used the self-
report of missed dose method to compare patient estimate of adherence with 
that of the TDA (n=34).  Ajit et al. found that patient reported adherence was 
below that of the TDA in the majority of cases.  In some cases patients reported 
100% adherence when their TDA indicated <40% adherence.  Similar reports 
have been published by Okeke et al. (70) and Kass et al. (76) and it appears 
therefore, that relying on patient reports of adherence in glaucoma studies is 
prone to error. 
  
   
42 
 
1.10.6.1 Brief Medication Questionnaire (BMQ) 
Svarstad et al (77) developed the Brief Medication Questionnaire (BMQ), a self-
report instrument for measuring and monitoring adherence from the a patient 
perspective.  The BMQ questionnaire has three parts; the regimen screen, 
belief screen and recall screen, to increase the sensitivity and positive 
predictive value and specificity level.  The frequency of missed-dose screen 
uses neutral, open ended-questions and a short recall period of a week.  The 
questionnaire was validated (n=20) using a Medication Events Monitoring 
System (MEMS) and the BMQ achieved a sensitivity level of 80-100% and 
accuracy of 95% (77). 
 
1.10.6.2 The Morisky Medication Adherence Scale (MMAS) 
The Morisky Medication Adherence Scale (MMAS) was reviewed in 1986 to test 
the validity of the structured four-item self-reported adherence measure in 
hypertensive patients. Results showed that 75% of the patients who scored high 
on the four-item scale at year 2 had their blood pressure under adequate control 
at year 5, compared with 47% under control at year 5 with a low score 
(P<0.001) (53). The MMAS tool has been used since as a four-item validated 
measure of self-reported adherence with systemic antihypertensives.  Although 
not validated for use in glaucoma patients, MMAS has been used in 
hypertension studies with a similar asymptomatic characteristic to that of 
glaucoma and thus has the potential to be useful for the latter condition.   
 
1.10.6.3 The Medication Adherence Rating Scale (MARS) 
The Medication Adherence Rating Scale (MARS) is a ten-item self-report 
measure of medication adherence developed by Thompson et al. (78).  The 
scale was adapted from the MMAS and Drug Attitude Inventory (DAI).  The new 
inventory was administered to 66 patients, the majority of whom were 
diagnosed with schizophrenia.  Lithium levels and carer ratings of adherence 
were used to check adherence in order to validate the new scale.  Using a 
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continuous scale to grade adherence rather than labelling a person either 
adherent or non-adherent has been an effective research tool (79). 
 
Using questionnaires that attempt not only to measure adherence but also to 
provide information about medication behaviour helps to implement appropriate 
adherence interventions.  There is a lack of literature comparing the different 
methods used to elicit which tools are preferred by patients, which take into 
account ease of use along with their reliability and usefulness as an adherence 
screening mechanism.  It is interesting to find evidence of VAS specifically 
designed to function as an easily administered assessment tool suggesting that 
other tools are not accessible to all patients regardless of literacy, although this 
has not been described in the reviewed literature. 
 
 
1.11  Potential predictors of non-adherence 
Clear predictors of non-adherence have not yet been established. 
Sociodemographic variables have been investigated previously but have not 
been shown to be accurate enough to ensure that patients at risk can be 
selected without the possibility of missing at risk individuals.  Other predictors of 
non-adherence need to be tested for glaucoma patients.  
 
1.11.1 The Satisfaction with Information about Medicines Scale (SIMS)  
Research has shown that patient‟s requirements for information about 
medicines varies among individuals to ensure that medicines are taken 
appropriately and that the likely risks and benefits are understood.  Thus, the 
quality of the information given to patients should be measured by the extent to 
which individuals perceived needs have been met in relation to their medication 
information (79, 80).  The SIMS offers a valid and reliable method of assessing 
patients satisfaction with medicines information that can be used to quantify 
information requirements (81).   SIMS is a questionnaire comprising of 17 items 
derived from published recommendations of the Association of the British 
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Pharmaceutical Industry.  SIMS is able to elicit the type of information that is 
required to enable safe self-management of medication (82). 
 
Three different analyses can be carried out from SIMS; medicine information 
profiles, total satisfaction rating and sub-scale scores of action and usage of 
medications and potential problems of medication.  A previous study carried out 
by Gellaitry et al., used SIMS methodology to profile patients satisfaction with 
information they have received about HAART (Highly Active Anti-Retroviral 
Therapy) among patients attending Human Immunodeficiency Virus (HIV) 
clinics in Brighton (82).  
 
The SIMS showed good internal reliability with a Cronbach α- coefficient of 
0.92.  Gelliatry et al. were able to conclude that individuals faced with treatment 
decisions varied widely in their perception of information they had received.  
Furthermore, those individuals who acted positively to the offer of HAART were 
more satisfied with the information they had received about treatment than 
those who declined it (82).  
 
The SIMS tool has been evaluated previously in a variety of clinical settings, 
both for ease of use, internal consistency and test-retest reliability (80).  
Although not validated for use in glaucoma patients, SIMS has been sampled in 
various disease and treatment characteristic groups including other 
asymptomatic conditions such as early diabetes or HIV infection.  Higher levels 
of satisfaction with medicines information have been shown to be associated 
with higher levels of reported adherence (80).  With this evidence, it is possible 
that SIMS will prove able to be used as a potential predictor of non-adherence 
to ocular hypotensive medication.  
 
Potential predictors of adherence are important as they not only improve patient 
long-term care but have the potential to reduce healthcare (eg National Health 
Service) expenditure. The additional costs of non-adherence in the 
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management of glaucoma could be avoided by being able to predict the areas 
that cause non-adherence and target them specifically. 
 
 
1.12  Conclusions 
 At the 2006 Annual Congress of the Royal College of Ophthalmologists, it was 
identified that there is an ongoing challenge in the education and counselling of 
glaucoma patients, particularly in the area of instruction for correct drop 
administration technique.  There was a call for new strategies to improve patient 
education, disease awareness and communication.  Previous research has 
largely focussed on oral solid dose therapy, whereas glaucoma patients use 
eye drops that may be more difficult to administer than pills.  There is a need to 
address the issues specific to non-adherence with topical medication. 
 
A review of the literature has revealed how an understanding of health 
behaviour models could be used to improve adherence.  Aiming for improved 
adherence with antiglaucoma therapy is an important objective in achieving 
patient adherence to glaucoma medication since evidence suggests that a 
degree of non-adherence with glaucoma treatment should be a risk factor for 
the progression of glaucoma.  It would appear that by increasing patient 
adherence there should be improvement in treatment effect and an associated 
reduction in overall health costs.  Reduction in surgical management would be 
of particular benefit since any invasive eye surgery is both costly, carries a risk 
of failure, can lead to sight-threatening complications and is rarely a patient 
preference. 
 
However to achieve an improvement in ocular hypotensive topical medication 
adherence, our understanding of the methodological principles of measuring 
adherence needs further development, the literature reviewed above revealing 
where past research studies have failed.  A discreet and effective way of 
measuring adherence and impact of an intervention is required.  
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Self-report methodology is easy to administer and analyse and is used 
frequently in adherence studies.  Discerning the agreement between self-report 
measures and an objective measure of adherence will help our understanding 
for the use of these methodologies.  It has been well documented that the 
effects of monitoring individuals to assess their level of adherence will affect 
their level of self-reported adherence but what the degree of this effect remains 
unknown. 
 
Clear predictors of non-adherence or reduced adherence have not yet been 
established for patients prescribed topical ocular hypotensive medications. 
Sociodemographic variables have been investigated previously but have not 
been shown to be accurate enough to ensure that patients at risk can be 
selected without the possibility of missing at risk individuals.  In addition, the 
evidence suggests that different degrees of non-adherence will lead to varying 
degrees of glaucoma progression.  A study is required to estimate the 
magnitude of adherence with antiglaucoma therapy and help our understanding 
of the varying degrees of non-adherence.  Once it is possible to measure 
adherence with an adequate degree of accuracy, reliability and repeatability, 
then high quality studies can be performed to determine how adherence levels 
can be improved.  
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2 Methods 
 
2.1  Aims 
This pilot study was designed to evaluate the feasibility of using the Travalert® 
Dosing Aid (TDA) as an adherence measure.  
 
 
2.2  Objectives 
The objectives of this study were to:  
 Estimate the agreement between the TDA and patient self-reported 
adherence. 
 Estimate the magnitude of adherence to travoprost for the treatment of 
glaucoma. 
 Identify any predictors of non-adherence to travoprost. 
 Estimate the effect of adherence monitoring on self-reported adherence. 
 Determine if reduction in IOP could be used as an adherence measure. 
 To identify any potential problems with the use of the TDA as an 
adherence measure. 
 To test participant acceptability of data collection tools. 
 
 
2.3  Method 
 
2.3.1  Overview 
A two month cohort study of adherence to glaucoma medication using 
questionnaires and an electronic adherence measure in individuals with 
glaucoma, or OH requiring treatment with travoprost eye drops.  
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2.3.2  Ethical and Research Governance approvals 
 The study received ethical approval from the Norfolk Research Ethics 
Committee (appendix 1) and research governance approval from the East 
Norfolk and Waveney Research Governance Committee (appendix 2). 
 
2.3.3  Sample Size  
Because there is no definition in the literature for an acceptable level of 
adherence, 80 % was chosen as a priori to represent what was believed to be 
an adequate level.  A sample size of 100 was selected to allow for the 
withdrawal of 4 participants with 96 participants giving an absolute deviation 
from the population of 8%. 
 
2.3.4  Sample population 
Patients attending the Norfolk and Norwich University Hospital Out-Patients 
Glaucoma Clinic were randomly approached and stratified by experience of 
travoprost use; patients already using travoprost and thus experienced drop 
users (follow-up group) and patients prescribed travoprost at the time of 
recruitment and thus drop naïve (newly prescribed group).  Stratification was to 
allow the following: 
 Estimation of the TDA impact on the eye drop use of the existing user 
group 
 Determination of whether the TDA presented new problems with 
administration for the follow-up group 
 Determination of whether the TDA presented problems with 
administration for a newly prescribed travoprost group 
 Identify any association between adherence and duration of treatment 
with travoprost. 
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2.3.5  Period of data collection 
The recruitment period was June 2009 – December 2009 and the duration of 
the observation was approximately 8 weeks.  The duration of data collection 
was thus 32 weeks.  
 
2.3.6 Participant identification 
Inclusion Criteria: 
The newly prescribed group:  
 Newly diagnosed or previously untreated glaucoma or OH patients 
(using established standard criteria as documented in the European 
Glaucoma Society Guidelines) (83) 
 
The follow-up group:  
 Treated glaucoma patients using travoprost, which had been shown 
to be efficacious with no hypersensitivity or other unwanted side 
effects  
 
Both groups:  
 Able to provide signed, informed consent 
 Adequate ability to read and understand English 
 Aged 18 or above 
 
Exclusion Criteria: 
 Patients whose travoprost eye drops would be applied by care home 
staff / home-helpers 
 Additional therapy required for treatment of glaucoma.  
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2.3.7  Recruitment 
Eligible patients were identified at the time of clinic consultation by their clinician 
and referred to the research assistant to explain the nature of the research and 
obtain consent following standard consent procedures.  If the research assistant 
was unavailable, the patient was contacted by telephone and verbal consent 
obtained followed by written consent in the post.  
 
 
2.4  Data collection  
Participants were given a demonstration of the TDA by one of the research 
assistants.  Socio demographic details were collected using a structured 
interview (see appendix 3).  The initial questionnaire was given to patients to 
complete at home and return in the pre-paid envelope provided.  Participants 
used the TDA for a period of approximately 8 weeks and either returned to the 
clinic as part of their routine follow-up care where the final questionnaire was 
issued and the Travalert device collected or, the questionnaire was sent in the 
post and a pre-paid envelope provided for collection of the TDA.  If the 
participant failed to return their questionnaire within two weeks of dispensing, 
the participant was telephoned to remind them.  Figure 2.1 shows the data 
collection points and the patient flow through the study.  
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Figure 2.1 The patient pathway
 
  
Clinic Attendance
Recruitment
Decline
Usual Care
Consent
Visit 1
Travalert Demonstration
Social Demographic informaton collected
Baseline Questionnaire issued
2 month monitoring of usual care
Visit 2
Discussion of experiences
Travalert Data Collected
Final Questionnaire issued 
End of Study
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2.4.1 Travalert® Dosing Aid 
Figure 2.2 illustrates the TDA which is a device designed to assist patients in 
taking travoprost that also records when drops are administered.  When a bottle 
of travoprost is inserted, the lever is pressed to squeeze out a drop.  A built-in 
memory chip records the time and day when the lever is fully depressed.  The 
TDA is designed not primarily as an electronic adherence monitor, but as an aid 
to dosing, it is easy to use, ergonomic and non-intrusive.  This overcomes the 
problem of some medication monitors which are difficult to use and can thus 
bias the participants who can be selected for such studies to those whom would 
be able to operate a more complex device.  
  
However, as the device is designed as an adherence aid it has two additional 
functions; an audible and visual dosing reminder; an intermittent beeping sound 
and a tear drop appears in the window at the time that dosing is required see 
figure 2.2a.  In order to ensure the TDA remained an adherence „monitor‟ rather 
than an adherence „aid‟, the audible alarm was switched off using the Travalert 
software at the time of TDA set-up.  The software does not allow the turning off 
of the visual reminder thus, a sticker was placed over this window to hide the 
tear drop, see figure 2.2b.  Participants were asked not to remove the sticker 
and shown that the bottom left hand corner of the screen is visible in case the 
battery symbol appears which would indicate that the battery needs changing.  
Participants were asked to contact the research unit if a new battery was 
required.   
 
Participants were shown how to use the TDA including how to replace the bottle 
themselves after collecting their repeat prescription via their General 
Practitioner.  Participants were also instructed to ensure the lever was fully 
depressed when apply their drops to ensure the TDA recorded the application 
of the drop.  Participants were asked to use the dosing aid to administer their 
travoprost eye drops as recommended by their clinician during their clinic 
consultation.  Participants continued using the TDA for an approximate 8 week 
period then returned their device so the usage data could be retrieved.   
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2.5 Questionnaire Design  
 
 
2.5 Questionnaires  
A questionnaire was designed to elicit patient medication taking behaviour and 
potential predictors of adherence.  The initial questionnaire requested the newly 
prescribed participant group to disregard questions relating to medication taking 
behaviour with travoprost.  The initial and final questionnaires are outlined in 
appendix 4 and 5 respectively. 
 
All questionnaires were provided at the baseline (initial questionnaire) and then 
post TDA monitoring (final questionnaire) in order to assess the following:  
 Patient acceptability of the questionnaire completion 
 Any impact of the TDA monitoring on patient questionnaire response  
  
2.5.1 Content 
The Questionnaires comprised of four distinct sections:  
 
Figure 2.2a TDA with visual 
reminder 
 
Figure 2.2b TDA with visual 
reminder obscured. 
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Section one 
 Determination of whether participant had previous experience of eye 
drop use. 
 Description of any problems experienced if eye drops had previously 
been used. 
 
Section two 
 Self reported adherence via two approaches; frequency of missed doses 
and the Morisky Medication Adherence Scale (MMAS) (53). 
 Additionally, any reasons for reported non-adherence were sought via 
providing the most frequently cited reasons plus an opportunity to report 
other reasons 
   
1.  Self reported adherence via frequency of missed doses during a one month 
period. 
In order to quantify the extent of non-adherence, participants were required to 
report missed dose frequency. Below is the sample of this question:  
On average, how many doses of your drops to you miss each month? 
□ None 
□ 1 dose 
□ 2-3 doses 
□ 4-9 doses 
□ 10-19 doses 
□ 20 or more doses 
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This scale was chosen in order to help participants quantify their missed dose 
frequency with ease.  The scale was then categorised into 5 adherence % 
groups for comparative analysis.  
None = 100% Adherent  
1 dose = 97% Adherent 
2-3 doses = 92 % Adherent 
4-9 doses =80% Adherent 
10-19 doses = 57% Adherent  
20 or more = Less than 50% 
For both groups, the data were used to compare the TDA missed dose rate to 
patient self-report of missed doses.  Additionally, for the follow-up group, a 
comparison of adherence between the initial and final visits allowed an estimate 
of the TDA effect accepting the limitation of a before and after study in terms of 
identifying causal links. 
 
2. Self reported adherence via MMAS  
The MMAS is a commonly used adherence screening tool (53).  MMAS is 
composed of four yes/no questions about past medication use patterns and it is 
thus quick and simple to use during drug history interviews.  Participants 
answering „yes‟ to a question score 1, thus scores ranged from 0-4.  
Participants who scored 0/1 were dichotomised to the adherent group, 
participants scoring 2-4 were dichotomised to the non-adherent group.  
However, the sensitivity of this test was unknown and thus further analyses 
used a 0 score to dichotomise the adherent group and 1-4 to dichotomise the 
non-adherent group.  Minor changes to the wording of the validated 
questionnaire were made in order to make MMAS relevant to eye drops and the 
final question was modified to read: “Do you ever forget to use your eye drops?” 
to provide more detailed information about the reasons for non-adherence.  
Below is the example of the modified question:  
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If you have missed using your eye drops, what has been the reason or reasons 
(if any) for missing them? 
□ Forgot 
□ Ran out of medication 
□ Experienced side effects 
□ Experienced difficulty in using the eye drops 
□ Other …………………………………………….. 
Participants who ticked the „forgot‟ box were attributed a score of 1 as per the 
scoring system used for MMAS.   
For the newly prescribed group, the data were used as an adherence screening 
tool.  For the follow-up group, this allowed a comparison of adherence between 
the initial and final visits as an estimate of the TDA effect. 
 
Section three 
 Satisfaction with Information about Medicines Scale (SIMS) 
An abbreviated 14-item version of SIMS was used to assess participants‟ 
perception of the information they had received from their clinician about their 
eye drops.  SIMS has previously been used to report the association of higher 
levels of adherence with greater satisfaction of medicine information, and lower 
levels of satisfaction with stronger concerns about the potential adverse effects 
of medicines (80).  Participants were requested to rate the information they had 
received about their medication using a response scale; „too much‟, „about 
right‟, „too little‟, „none received‟, and „none needed‟.  The wording of the 
questions was adapted in order to relate to eye drops. 
 
Collection of this data at the initial visit and final visit allowed a comparison of 
any changes in participant attitudes towards the information required for safe 
eye drop administration during the periods of adherence monitoring.  It also 
allowed the testing of patient acceptability of questionnaire completion. 
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Section four 
 Additional information sought  
“Is there anything that you would like more information about that we have not 
mentioned?” 
“Have you looked for any additional advice or information about glaucoma from 
other independent sources such as leaflets or the internet?” 
 
 Existing medication regimes 
“Do you currently take any other medication on a regular basis? 
“If yes do you use your glaucoma medication at the same time as you take your 
other medication? 
 
 Help received to apply eye drops 
“Do you apply your glaucoma eye drops yourself or does somebody help you?” 
The same questions were given at the start and finish of the study to enable the 
review of attitudes before and after the adherence monitoring period to provide 
evidence of any effects adherence monitoring may have and patient 
acceptability of questionnaire completion.    
 
2.5.2  Assessment of face validity  
A test or questionnaire has face validity when it appears valid to those who 
complete the questionnaire.  A test that seems relevant to the lay person is said 
to have “face validity” (84).  Face validity was sought from non-clinical hospital 
staff.  Four colleagues were randomly selected to view three different versions 
of the same questionnaire and comment on: 
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1. Overall readability and formatting 
2. Ease of use 
3. Understanding of the questions 
4. Other general comments 
There was one questionnaire that was chosen over the others for ease of use 
due to its clear and bold formatting and „tick box‟ grid.   
 
 
2.6  Intraocular pressure measurements 
Participant IOP values were measured by Goldmann applanation tonometry.  
The time points of the IOP assessments used were different for each group: 
 Newly prescribed group – IOP recorded during their consultation with the 
clinician just before recruitment and again at the participant follow-up 
appointment at the time of their final visit.  Thus, only those participants 
who received IOP measurements after 8-weeks as part of their routine 
follow-up care had this data collected.   
 Follow-up group – the IOP recording documented in their eye note 
records at the time of starting treatment with travoprost and the last 
documented IOP measurement in the patient ophthalmic records.  Thus 
the time period between the IOP measurement at baseline and follow-up 
was greater than the 8-week period used in the new travoprost user 
group.  Participants, who had switched from any other IOP lowering 
treatment to travoprost without a treatment break, did not have baseline 
untreated IOP data available. 
 
The mean IOP (in mmHg) from the right and left eye were calculated for both 
the initial and final visit.  For participants using travoprost in only one eye, the 
IOP measurement from the treated eye was used.  The difference in IOP 
measurements between the initial and final visits was compared to the 
adherence percentage rate to determine if this revealed a correlation. 
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2.7  Demographic and clinical information  
Demographic and clinical information were obtained by one-to-one structured 
interview carried out between participant and research assistant.  A full copy of 
the social demographic and medical history questionnaire is provided in 
Appendix 3.  Data collected included date of birth, gender, ethnic origin, 
employment, level of education, family members affected by glaucoma, marital 
status, and general medical history.   
 
 
2.8  Participant trial design issues 
On study completion, participants were engaged in a 10 minute semi-structured 
interview via telephone or face-to-face.  Face-to-face was used for the newly 
prescribed group that were attending their routine two month follow-up visit.  
Telephone conversation was adopted for any participants, particularly the 
follow-up group, that were not attending a two month follow-up visit as part of 
routine care.  The interviews were designed to capture participant opinion 
regarding the following trial aspects: 
1. Ease of questionnaire completion and approximate time taken 
2. Ease and acceptability of the TDA 
The discussion template is shown in appendix 5. 
 
 
2.9  Data analysis 
 The patient population was characterised by using descriptive analysis. 
 The magnitude of adherence was reported by using descriptive analysis.  
 Cohen‟s Kappa was used to measure the agreement between the TDA 
score and patient self-reported adherence.  
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 A Fisher-exact test was used to measure the association between non-
adherence with non-completion of the MMAS and frequency of missed 
dose questionnaires, and problems encountered with the TDA. 
 TDA data were dichotomised into adherent or non-adherent and logistic 
regression was used to identify possible predictors of adherence.  
 Variation in adherence with the TDA monitoring period was identified 
using ANOVA.  
 McNemar tests were used to test for association between satisfaction 
with information received about travoprost before and after monitoring. 
 Spearman‟s co-efficient tests were used to test the relationship between 
the number of days using travoprost and satisfaction with information 
received, and magnitude of difference in IOP and adherence. 
 
2.9.1 Calculation of Travalert® adherence score  
The TDA was pre-set with the patient study number and date of birth for 
identification purposes.  The TDA is also set with the patient preferred dosing 
time +/- 2 hours and whether it was unilateral or bilateral dosing.  The electronic 
data are extracted and adherence calculated by software using the following 
calculation:  
                 
                               
                                
                               
        
However, it is known that the device has the potential to make extra recordings 
when the lever is depressed erroneously (69).  Thus, more than 1 dose taken 
per eye per day was not counted in the adherence rate calculation, therefore 
making uni-/bil-ateral dosing irrelevant to the adherence calculation.  In addition, 
the Travalert software relied upon the patient specifying what time they 
expected to dose +/- two hours, so this could be pre-set at the time of their 
initial consultation.  For the newly prescribed group, they may not have had the 
opportunity to think about or know how using eye drops would fit into their daily 
regimen, therefore making discussion about the agreed dosing time particularly 
difficult and arbitrary.  It was felt that if this regimen was not complied with and 
they actually found that they regularly used their drops earlier or later than this 
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agreed time, it would suggest that the patient was non-adherent, leading to 
false reporting of adherence. 
 
Therefore, a mathematical programme that calculated adherence from the TDA 
data collected from the TDA was designed to calculate the mean time of dosing 
over the period of monitoring.  The use of this programme ensured the TDA 
could be dispensed to the patient without the need for a pre-specified dosing 
time, thus allowing the patient to dose at a time to fit in with their own regime, 
generating a more naturalistic adherence monitor.  
 
However, the TDA data used the 24 hour clock which did not conform to 
statistical summary measures using means and standard deviations.  For 
example, if a dose was taken at 23:59 the first night and 00:01 the second night, 
the mean average time would be calculated to 12:00 (noon) when it should be 
00:00 (midnight).  However, circular data analysis was used to convert time to 
degrees from which an average degree could be found and then converted 
back to a time. 
 
The prescribing information for travoprost states that it should be used in the 
„evening‟.  Patients are rarely given any further dosing instructions by their 
clinicians other than they may be encouraged to use the drops „before they go 
to bed‟.  There is no agreement on the exact time that travoprost should be 
used and thus an evening dosing time of between 5 pm and 5 am has been 
assumed.  Any dose that falls outside of these time points was classed as non-
adherent.   
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The following calculation was used to calculate adherence % by the adherence 
calculator: 
                                                                       
            
               
                     
                                      
       
 
2.9.2 Identifying predictors of non-adherence 
Regression analysis was used to determine the relative importance of any 
factors identified as being associated with adherence.  A linear relationship 
between measured non-adherence was unlikely to exist given the positively 
skewed distribution and thus adherence was treated as a dichotomous variable:  
 Adherent = if the score is ≥to 80%  
 Non-adherent = if the score is < 80% 
Logistical regression analysis was used to examine the effect of potential 
explanatory factor in a univariate model by estimating the odds ratio of 
adherence along with the corresponding 95% confidence interval and p-value.  
Forward selection was used to select the independent factors for constructing a 
multivariate model in a structured fashion.   
 
2.9.3 Examination of poor agreement between participant self-report and 
TDA adherence measures 
A Cohen‟s Kappa test was used to measure agreement between MMAS and 
the TDA adherence score.  A Fishers-exact test was used to measure 
agreement between non-completion of the questionnaires and non-adherence.  
The effects of monitoring adherence on patient self-report was also analysed by 
comparing the self-reported adherence levels before and after the monitoring 
period using a McNemar Test.   
 
2.9.4 Satisfaction with information about travoprost  
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1. SIMS scored from 0 to 14 with a score of 0 indicating complete 
dissatisfaction and 14, complete satisfaction.  A median (IQ) SIMS score was 
calculated for each participant. 
 
2. A total satisfaction rating was obtained by summing the scores of each item.  
If participants endorsed the information received by reporting „about right‟ or 
„none needed‟, they received a score of 1.  If participants were dissatisfied 
with the information received reporting „too much‟ too little‟ or „none received‟, 
a 0 score was given.  Thus scored ranged from 0 to 14 with high scores 
indicating a high degree of overall satisfaction with the medication 
information received concerning travoprost. 
 
3. The mean SIMS score for each information profile was compared to reveal if 
there were any differences in the initial SIMS report and the final SIMS report 
for each individual.  
 
2.9.5 Association between IOP and adherence 
Only those participants who have baseline untreated IOP measurements were 
used.  (In some cases, participants were using a different form of IOP lowering 
medication before switching to travoprost.)  IOP measurements were obtained 
from the time Travoprost was started through to the last documented IOP 
measure as recorded in their ophthalmic records.  For the newly prescribed 
group this was at the time of recruitment through to the 8 week follow-up visit 
where available.  
 
2.9.6 Identify any potential problems with the use of the TDA and 
questionnaires as reliable measures for use in a full trial 
 
Notes were taken of the participant responses during the semi-structured 
interview at the end of the study.  These transcriptions were analysed using 
inductive coding and then evaluated for extensiveness.  For example, 13 codes 
emerged for the for the question, how long did it take you to complete the 
questionnaire; 2 mins, 3 mins, 5 mins, 10 mins, 5-10 mins, 15 mins, 20 mins, 30 
mins, “a short time, not long, quickly”, and “don‟t remember completing it”.  
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These codes were then combined to reveal 5 main categories and the number 
of responses for each category counted.  Questions relating to use of the TDA 
were coded into themes and frequency reported. 
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3 Results 
 
3.1 Sample demographics 
From the 100 patients invited to participate, 98 consented and completed the 
necessary documentation.  The number of participants stratified to the „follow-
up group‟ was 49 and a further 49 to the „newly prescribed group‟.  Table 3.1 
summarises the demographic characteristics of the sample population.  It can 
be seen that the „follow-up‟ and „newly prescribed‟ groups were well matched in 
terms of age and gender distribution.  The „newly prescribed‟ group did however 
have a greater proportion of employed and those who left school at 16 years of 
age, whereas the follow-up group had a greater proportion of people with 
significant previous / current medical conditions. 
 
Table 3.1  Population demographics 
 Total 
cohort 
(n=98) 
Follow-up 
group 
(n=49) 
Newly 
prescribed 
group (n=49) 
Gender No. (%) Male 51 (50%) 22 (45%) 29 (59%) 
Age 
(n=98) 
Years, Median 
 (IQ) 
72 
(63, 78) 
72 
(63, 78) 
70 
(62,78) 
Employed   
(n=92) 
No. (%) Yes 
72.8 
(67%) 
25 (51%) 38 (83%) 
British 
(n=97) 
No. (%) Yes 
96.9 
(95%) 
49 (100%) 46 (94%) 
Married/Partner (n=91) No. (%) Yes 
73.6 
(67%) 
32 (70%) 35 (78%) 
Education 
(n=90) 
No. (%) Left 
school at 16 yrs 
55.6 
(50%) 
19 (43%) 31 (67%) 
Family members with 
glaucoma (n=79) 
No. (%) No 
65.8 
(52%) 
25 (68%) 29 (69%) 
Previous / current 
medical condition (n=91) 
No. (%) Yes 
58 
(63.7%) 
33 (73%) 25 (54%) 
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Further sub-categorisation defined the employment status of the sample 
population as 25 (27.2%) in paid employment, 66 (71.7%) retired and 1 (1.1%) 
participant unemployed.  The marital status was 68 (74.7%) married, 13 
widowed (14.3%), 7 (7.7%) divorced or separated, and 3 (3.3%) single.  The 
education status was 26 (28.9%) had undertaken some form of certification, 
apprenticeship or diploma, 26 (28.9 %) had left school at age 16, 23 (25.6%) left 
school before they were age 16, 6 (6.7%) left school at age 18 and 9 (10%) had 
a degree. 
 
 
3.2 Data from the TDA  
Data from the TDA were collected from 88 participants, TDA data were missing 
from 10 participants for the following reasons: 
 Participant did not return the TDA (2) 
 Failure of the TDA (1) 
 Participant decided not to use the TDA - preference for manual delivery 
of drops (4) 
 Participant lost to follow-up (2) 
 Participant stopped treatment due to illness (1) 
 
3.2.1 Comparison of the Travalert® software adherence calculation and 
the adjusted adherence calculation 
Before accepting the adjusted adherence calculation described in section 2.9.1 
as the methodology to report TDA % adherence, a comparison of the 
magnitude of difference between the % adherence rate calculated by Travalert® 
software and the adjusted adherence calculator was made (N=88).  Figure 3.1 
shows the scattergram of these results; the mean difference was 20.33 (SD 
21.98); indicating that the calculation of adherence by the adjusted adherence 
calculator increased the adherence rate.   
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Figure 3.1  The magnitude of difference between the adherence scores 
calculated by the Travalert® Software and adjusted adherence calculation 
 
 
 
It can be seen that at high levels of adherence, agreement between the two 
calculation methodologies was good.  However, when the Travalert® adherence 
rate was low, the difference was greater.  One notable deviation was a -52.49% 
difference in adherence as a result of the patient stopping use of the drops after 
22 days due to developing a Bell‟s palsy.  The Travalert® registered that 18 of 
those 22 days were adherent resulting in 82% of doses being adherent.  
However, the period of travoprost use was actually 61 days thus adherence to 
the regimen was only 29.51%.  At lower adherence levels, however, the most 
frequent reason for the discrepancies was dosing times being set incorrectly.  
An example being the 84.31% difference in adherence due to the estimated 
dosing time discussed at the initial consultation being set too late in the 
evening.  Thus, when the patient actually used their travoprost earlier in the 
evening, the device only registered 8% of doses being within the 4 hour 
adherent window.  However, the pilot study data calculator averaged the mean 
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dosing time to be earlier in the evening and thus registered 92.31% of doses as 
adherent.   
 
Given the deviations between the Travalert® software calculations and adjusted 
adherence calculations, together with the rationale for these deviations, the 
adjusted adherence calculator was used for this study to report the percentage 
adherence score. 
 
 
3.3 Adherence 
Using the TDA adjusted adherence calculation, the median adherence was 
86.89% (IQ 60.83, 96.15).  Figure 3.2 illustrates the distribution of the Travalert 
scores for the 88 participants, the positive skew indicating that the majority of 
participants had high percentage adherence.  
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Figure 3.2  Distribution of TDA Scores 
 
 
3.3.2   Comparison of adherence measures 
The measure of adherence was collected using three different methods TDA as 
described in section 2.9.2, MMAS and frequency of missed dose (FMD) as 
described in section 2.5.1.  Table 3.2 compares the results of the three different 
methodologies.  The patient self-report methodologies (MMAS and FMD) found 
almost 100% adherence.  Further examination of the MMAS scores reveals that 
72 participants categorised themselves as having perfect adherence, 9 
moderate and 1 poor and so using this more sensitive scoring system, greater 
non-adherence is detected.  The FMD questionnaire revealed that 57 
participants reported being 100% adherent and 13 being 97% adherent. 
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  % non- adherent 
participants 
Travalert  Dosing  Aid (n=88) 
≥ 80% is adherent , < 80% is non-adherent 
40.9% (n=36) 
MMAS (n=82) 
= 0/1 is adherent, 2/3/4 is non-adherent 
 1.2% (n=1) 
= 0 is adherent, 1/2/3/4 is non-adherent 12.2% (n=10) 
FMD (n=70) 
≥ 80% is adherent 
0% (n=0) 
 
 
3.4 Agreement between TDA and self-report 
Table 3.3 shows a cross tabulation of both self-report methodologies (FMD and 
MMAS) compared to the TDA adherence score.  A Cohen‟s Kappa test was 
used to measure the agreement between MMAS (applying the sensitive scale, 
only 0 being adherent) and TDA adherence score.  The result indicated a slight, 
but not significant, disagreement.  Furthermore, 4 participants have reported 
non-adherence despite being TDA adherent.  This suggests patient over-
reporting of non-adherence. 
  
Table 3.2  Comparison of adherence using the three different adherence 
measures 
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Table 3.3  Comparison between TDA identified non-adherence to self-
report measures.  
 
 
3.5 Examination of poor agreement between participant self-
report and TDA adherence measures 
Only 70 participants completed the final FMD questionnaire and 82 participants 
completed the final MMAS questionnaire.  Table 3.4 illustrates the distribution of 
self report respondents compared with TDA recorded adherence. 
 
Table 3.4   Association of non-completion of the Morisky and FMD 
questionnaire to adherence. 
 
 
TDA (N=88) Association 
(Fishers 
Exact) 
Adherent 
n (%) 
Non-adherent 
n (%) 
Final MMAS Questionnaire (n= 82) 
Completed (84%) 47 (53) 30 (34) 
p = 0.346 
Not-completed 5 (6) 6 (7) 
Final FMD Questionnaire (n=65) 
Completed (66%) 43 (49) 22 (25) 
p = 0.029* 
Not completed 9 (10) 14 (16) 
*Statistically significant 
Self Report Measures 
(n=64) 
TDA 
Adherent  
(n) 
TDA non-
adherent 
(n) 
% 
Agreement 
(Kappa) 
Morisky adherent 39 20 92.2 -0.056 
(p=0.525) Morisky non-adherent 4 1 7.8 
FMD adherent 43 21 100 
N/A 
FMD  non-adherent 0 0 0 
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The results revealed that more non-adherent participants did not complete the 
final FMD than the final MMAS questionnaire.  There was a statistically 
significant relationship between not completing the Final FMD Questionnaire 
and non-adherence, suggesting that adherence might affect completion of this 
questionnaire.  It is not known why more people completed the final MMAS 
questionnaire, but as the percentage rate of those completing the 
questionnaires was lower for FMD Questionnaire any further analysis would be 
biased. 
 
3.5.2 Effect of the TDA on self reported adherence 
The initial and final MMAS questionnaires were fully completed by 37 
participants. Using the sensitive MMAS score (0 score = adherent, 1/2/3/4 = 
non-adherent), the initial MMAS questionnaire identified 13 (13.3%) participants 
as non-adherent and the final MMAS questionnaire identified 8 (20.5%) 
participants. A matched pairs test comparing the initial and final MMAS scores 
found no difference in self-reported non-adherence after 2 months of monitoring 
(p = 0.125, McNemar Test).  Of the 24 participants completing the initial and 
final MMAS there was one participant initially reporting to be adherent who then 
reported non-adherence after 2 months, and those reporting non-adherence 
initially were still reporting non-adherence after 2 months.  The results 
suggested that monitoring with the TDA did not affect adherence.  
 
 
3.6 Demographic characteristics  
The following comparisons between demographic characteristics and other 
possible predictors of adherence were carried out using adherence as a 
dichotomous variable.  Due to ethnicity of the group being predominantly a 
British population (97%), the effect of ethnicity on adherence was not analysed. 
The results are summarised in table 3.5.  
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Table 3.5  Comparison between adherence and demographic 
characteristics   
 Adherent Unadjusted Selected* 
Variable Yes No (%) 
OR 
(95% CI) 
p-value 
OR 
(95% CI) 
p-value 
Gender 
 Male 26 20 (43.5) 
1.25 
(0.53,2.93) 
0.608 - - 
 Female 26 16 (38.1) 1  
 
 
 
Age       
Mean age 71 71 
0.995 
(0.95, 1.04) 
0.836 - - 
Education 
Left school <=16 30 17 (36.2) 
0.79 
(0.33,1.93) 
0.610 - - 
Further Education 
>16 
21 17 (41.7) 1 
 
 
  
Marital status 
Married/partner 33 26 (44.1) 
1.688  
(0.60, 4.75) 
0.321 - - 
Not married / partner, 
widowed or single 
15 7 (31.8) 1    
Employment 
Employed 34 27 (44.3) 
0.63 
(0.22, 1.78) 
0.383 - - 
Not employed/retired 14 7 (33.3) 1  
 
 
 
Administration of travoprost 
Self administered 34 23 (40.4) 
1.353 
(0.47, 3.87) 
0.573 - - 
Administered with 
help 
14 7 (33.3) 1  
 
 
 
Previous / current medical conditions 
Yes 32 23 (41.8) 
1.366 
(0.54, 3.48) 
0.513 - - 
No 19 10 (34.5) 1  
 
 
 
Medication naïve 
Yes 11 4 (26.7) 
1.932  
(0.55, 6.74) 
0.301 - - 
No 37 26 (41.3) 1    
Other medication administered at same time as travoprost 
Yes  10 5 (33.3) 
0.643 
(0.19, 2.17) 
0.476 - - 
No 27 21 (43.8) 1  
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*using forward selection 
Period of monitoring days was the only independent factor of significance 
affecting adherence.  The scattergram in Figure 3.3 shows that the longer the 
period of monitoring, the greater the level of non-adherence.  A Spearman‟s rho 
correlation analysis shows r=-0.236; p=0.028. 
  
 Adherent Unadjusted Selected* 
Variables 
Yes  
n 
No (%) 
n 
OR 
95% 
p-value 
OR 
(95%) 
p-value 
Family member with glaucoma 
Yes 13 11 (45.8) 
1.862 
(0.68, 5.10) 
0.227 - - 
No 33 15 (31.3) 1  
 
 
 
Additional information about glaucoma sought from independent source 
Yes 15 9 (37.5) 
0.990 
(0.37, 2.68) 
0.984 - - 
No 33 
20 (37.7) 
 
1    
Problems experienced using eye drops 
Yes 15 13 (46.4) 
1.787 
(0.69, 4.64) 
0.232 - - 
No 33 16 (32.7) 1 
 
 
  
Period of travoprost usage 
Mean period of use in 
days 
339 383 
1.000 
(1.00, 1.00) 
0.682 - - 
Total Satisfaction with SIMS 
Mean score 9 8 
0.897 
(0.79, 1.02) 
0.088 - - 
Difference in level of IOP after 2 months  
Mean IOP in mmHg  6 7 
1.030 
(0.94, 1.13) 
0.517 - - 
Period of monitoring days 
Mean no. of days 57 94 
1.026 
(1.00, 1.05) 
0.024 
1.076 
(1.01, 
1.15) 
0.022 
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Figure 3.3  Comparison of % adherence and period of monitoring with 
the TDA. 
 
 
 
 
However, adherence appeared to decline after 100 days of monitoring.  Thus, 
rather than looking at the correlation as a linear trend, the period of monitoring 
was split into quintiles.  The mean percentage adherence of each quintile was 
plotted to look at a non-linear trend.  The results are shown in Figure 3.4 and 
the highest percentage adherence was for participants who were monitored for 
51 – 75 days (n=44), which was the target period of monitoring for this study 
(42-70 days), but greater non-adherence was seen after 100 days of monitoring 
(ANOVA F=2.970, p=0.024).  However there were only 6 participants monitored 
for 101-125 days.  
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Figure 3.4  Comparison of % adherence and period of monitoring with 
the TDA using quintiles 
 
 
 
 
3.7 Satisfaction with information about travoprost 
The initial satisfaction with information about travoprost questionnaire was 
completed by 90 participants.  Scores can range from 0 to 14 with high scores 
indicating a high degree of overall satisfaction with the information received 
about travoprost. The median SIMS score for this group was 8.5 (IQ 5, 12).  The 
final satisfaction with information about travoprost questionnaire was completed 
by 83 participants, with a median of 9 (6, 11).  The results for both 
questionnaires are shown in Figure 3.5.  
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Figure 3.5 Comparison of the initial and final SIMS questionnaire results 
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3.7.1 Baseline SIMS  
Participants were more dissatisfied with the information received at the 
beginning of the study as reported in the initial questionnaire.  The lowest 
satisfaction scores were reported for „how to tell whether the medication is 
working‟, 31 participants (n=85) reported being dissatisfied and „how long it will 
take to act‟, 37 participants (n=86).  The highest satisfaction with information 
received was reported for „what your drops are for‟ reported by 82 participants 
(n=89). 
 
3.7.2  SIMS at completion 
In general, participants were more satisfied with information received at the end 
of the study, reported in the final questionnaire.  At this time point, the lowest 
satisfaction with information given was „whether eye drops will interfere with 
other medications‟ 35 participants (n=81) reporting dissatisfaction.  Conversely, 
the greatest satisfaction was reported by 78 of participants (n=79) with the 
information received about „how to receive a further supply of eye drops‟.  
 
The most substantial differences were for „How to obtain a further supply of eye 
drops‟, 11 people (12.8%) were not satisfied with this information initially but 
after two months only 1 participant (1.3%) was not satisfied with this information 
(no McNemar analysis possible), „how to apply eye drops‟, 14 participants 
(15.6%) were not satisfied with this information but after two months only 3 
(3.7%) were not satisfied (p=0.012), and „what you should do if you forget to 
take a dose‟ had reduced from 32 (38.6%) participants to 16 (20.5%) (p=0.007).  
In a further 4 categories the satisfaction of information increased over the two 
months but no significant association was shown.  Conversely, in 7 categories 
participants reported being less satisfied about their medication information 
after two months, but no significant association was evident. 
 
In addition, since there were two different groups of participants (the newly 
prescribed travoprost group and the follow-up travoprost group), possible 
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differences in these two groups were analysed.  There was no significant 
relationship (Spearman‟s correlation coefficient) between the number of days 
that a patient had reported receiving travoprost therapy and satisfaction with 
information received (r=0.039, p=0.720).  
 
 
3.8  Association between IOP and adherence 
Data were available for 88 participants, 40 from the follow-up group and 48 from 
the newly prescribed group. Data were missing for the following reasons:  
 No baseline untreated IOP available due to switching to travoprost from 
another IOP lowering eye drop (10, follow-up group) 
 No follow-up data (1, newly prescribed group) 
 
Participant baseline untreated IOP (in mmHg) was compared with final IOP 
measurement to calculate the magnitude of difference.  Figure 3.6 shows the 
correlation between percentage adherence rate and magnitude in IOP 
difference.  A Spearman‟s rank correlation confirmed a weak, non-significant 
correlation of r=0.155; p=0.179. 
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Figure 3.6  Correlation between percentage adherence rate and 
difference in average IOP at baseline (untreated) and 
completion (treated). 
*Mean IOP of both eyes if both eyes treated or, one eye if only one eye treated.  
 
In order to investigate if period of travoprost use was the reason for the weak 
correlation, the cohort was split into its two groups.  The newly prescribed group 
difference in IOP measurement was calculated over period of 368 days (IQ 
range 56, 560) and the follow-up group 646 days (IQ range 197, 918).   A 
Spearman‟s rho correlation analysis showed a weak positive correlation 
r=+0.088; p=0.627 for the follow-up group. The weakest positive correlation of 
the two groups was seen in the newly prescribed group of r=+0.034; p=0.826).  
The results suggest that the difference in time elapsed between baseline and 
follow-up measure had no effect on the correlation between IOP reduction and 
level of adherence. 
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With evidence to suggest that in some cases, particularly in patients with NTG, 
the magnitude of reduction in IOP can be an arbitrary measure and because no 
correlation was found with magnitude of difference in IOP from untreated to 
treated IOP measure, the final IOP measure was correlated with the percentage 
adherence rate.  A Spearman‟s rho correlation analysis showed a weak positive 
correlation of r=+0.106; p= 0.358.  The 30 non-adherent participants had a 
slightly lower mean IOP (15.9 ± 4.1) and the 47 adherent participants had a 
higher mean IOP (16.4 ± 4.5), this being the opposite of what would be 
expected.  These results suggested that level of IOP and magnitude of 
reduction in IOP cannot be used as an indicator of adherence.  
 
 
3.9   Potential problems with the use of the TDA  
Data were available for 93 participants, but not all participants answered every 
question during the discussion.  Table 3.6 summarises the comparison between 
the newly prescribed and follow-up groups.  To test for functionality of the TDA 
on the TDA adherence measure itself, a Chi-Squared test showed that 
problems with the device, inconvenience and difficulty of use did not have a 
significant effect on adherence. 
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Table 3.6  Summary of participant views of TDA use and affect on 
adherence. 
 Use of the TDA 
New 
Group 
Existing 
Group 
Fishers- 
Exact 
Total Group (n=69)* 
No 
n (%) 
No 
n (%) 
Non-
adherent 
n (%) 
Chi 
Squared 
Were there any 
problems? (n=84) 
29 (66) 29 (66)  (p=0.638) 10 (15) (p=0.237) 
Was it convenient? 
(n=80) 
4 (10) 12 (29)  (p=0.050) 7 (10) (p=0.134) 
Was it easy to use? 
(n=75) 
2 (6) 12 (31)  (p=0.007) 7 (10) (p=0.134) 
*Incomplete data as TDA data only available for 88 participants and not all 
participants answered every question regarding TDA usage. 
 
The majority of participants had no problems using the TDA and that it was 
convenient and easy to use.  The follow-up group found the device less 
convenient and less easy to use than the newly prescribed group, but both 
groups encountered the same amount of problems with the TDA.  The problems 
encountered with the TDA are summarised in Table 3.7.  No participants 
reported any problems with loading the TDA with their travoprost eye drop bottle 
or changing it after 28 days of use.   
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Table 3.7 Summary of problems encountered with the TDA 
 
Dispensing issues n=38 No (%) 
Didn't dispense drops consistently 18 (47.3) 
Sometimes you have to press lever more than once 8 (21.1) 
Too slow to dispense drops  3 (7.9) 
When bottle becomes empty you need to tap it to release the drop 1 (2.6) 
Difficult to know if lever has been pressed properly 1 (2.6) 
Device didn't dispense when 2/3 empty so was wasteful 2 (5.3) 
Didn't always work when dosing  the second eye 2 (5.3) 
Had to shake it to get drop out 2 (5.3) 
Concerned that maybe too much coming out 1 (2.6) 
Reason for non-use n=13 No (%) 
Stopped using it as felt it didn't work properly 3 (23.1) 
Prefers to deliver drops manually 6 (46.2) 
Kept poking eye with it so stopped using it 1 (7.7) 
Patient never even tried device decided it would be easier by hand 1 (7.7) 
No feeling in fingers and had to stop using it 1 (7.7) 
Threw device away - didn't like using it 1 (7.7) 
Other n=19 No (%) 
Didn't like using the eye guide 16 (84.2) 
Sometimes forgot to remove lid 2 (10.5) 
Not convenient when travelling 1 (5.3) 
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3.10 Potential problems with the use of the questionnaires  
Data were available for 85 participants.  The time taken for participants to 
complete the questionnaire is summarised in figure 3.7. 
 
Figure 3.7 Time taken for participants to complete the initial 
questionnaire 
 
All participants (89%) completed the initial questionnaire within 30 minutes, with 
80% reporting achievement within 10 mins or a time frame considered “short”, 
„not long‟ or „quickly‟.  The remainder of participants reported that they did not 
remember completing the questionnaire.  The results from the discussion 
questions found the majority of participants had no problems completing the 
questionnaire; 70% did not encounter any problems with the questionnaire, 74 
% did not find any questions difficult to answer and 74% were sure about what 
information questions were requesting.   
40%
≤ 5 mins
27%
5-10 mins
9%
15-30 mins
13%
Short time...
11% 
Didn't 
remember
5 mins and under
5-10 mins
15 – 30 mins
"short time" / 
"not long" / 
"quickly"
   
87 
 
 
 
 
 
 
 
 
Chapter 4 
Discussion 
  
   
88 
 
4 Discussion 
 
The relationship between adherence and sociodemographic factors such as 
age, sex, race, intelligence and education remains complex, and thus a random 
selection of participants was appropriate.  Unfortunately, due to a largely White 
British cohort the findings of the present study may not be generalisable to all 
UK populations since ethnicity has been associated with adherence (23).  
Further studies are needed to investigate the effect of ethnicity on adherence 
with anti-glaucoma therapy.   
 
Adherence studies may be fundamentally biased by the very selection of 
patients who attend follow-up care appointments.  Non-adherent patients are 
more likely to drop out of follow-up care and thus be missing from random 
selection (85).  Although it is not possible to account for those patients who had 
dropped out of care, it can be demonstrated that non-adherent participants had 
contributed to the findings through some participants‟ own admission of non-
adherence.  Theoretically, the sample was made up of more adherent patients 
(those who attend follow-up care being those more likely to be in the sample 
and agreeable to taking part in such a study); the magnitude of non-adherence 
may be even greater in the wider UK glaucomatous population than 
represented here.  Thus, caution must be taken when extrapolating these 
results.  
 
The TDA is limited to the use of travoprost, and thus this guided our study 
design to only include participants requiring travoprost.  Although this could 
have been a limiting factor, it was standard practice for all newly prescribed 
patients to be given travoprost at this out-patient clinic at the time of carrying out 
this pilot study and thus was of no consequence.  However, findings can only be 
generalised for the patient population using once daily prostaglandins, rather 
than more complex dosing regimes that some glaucoma patients may be using.   
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Despite the potential limitations, the sample selected provided a good 
representation of the UK population demonstrated by an appropriate gender, 
educational background and employment status distribution.  Furthermore, the 
age range was illustrative of a glaucomatous population (16).  
 
The results were also encouraging in terms of the ease with which the TDA was 
reportedly used and that there was no demonstrable impact on adherence 
accepting the limitation of a before and after study.  These findings endorse 
previous reports of TDA use which found that 97% of recordings were accurate 
in novice TDA users (69). 
 
In pre-study testing, it was thought possible for patients to dose by only partially 
depressing the lever on the TDA without the TDA actually recording the dose.  
This has not been reported in any previous literature that has assessed the use 
of the TDA.  To overcome this problem for the present study, participants were 
instructed to depress the lever all the way down.  This „intervention‟ might have 
heightened participant awareness of being monitored, which is a 
disappointment when the TDA had the potential to be a more discrete 
monitoring device.  Future studies should account for these possible 
inadequacies and ensure that patients are instructed appropriately to avoid 
misuse of the adherence recording aspect of the device. 
 
As previous studies have reported that the TDA can make extra erroneous 
recordings (69), in the present study, if more than one dose appeared to have 
been taken per day, this was not counted in the percentage adherence 
calculation.  Therefore, it was not reliable in assessing if the correct dosing was 
applied each day.  This is a limitation of using the TDA to assess adherence, 
since it means over-adherence cannot be reliably recorded.  Although the 
methodology is not fully described, Ajit et al. (34) also reported using an 
adjusted adherence measure for the TDA, treating multiple recorded doses 
within a 4-hour time period as a single dose. 
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During the two months of follow-up, missing data were primarily due to 
participant non-use of the device or not returning the device for data retrieval.  
Thus, at recruitment in any future studies, it should be made clear to 
participants that they must be prepared to pursue TDA use during the study 
period and be encouraged to ensure it is returned for collection of the data.  Or, 
it may be appropriate to screen patients for ability and willingness to use the 
TDA prior to study inclusion to minimise subsequent drop out. 
 
In addition, the TDA data works on the assumption that the eye drops were 
successfully dosed, when all that can really be inferred is that the patient 
attempted a dosing event at a specified time.  There is no way of knowing that 
the eye drop was successfully administered.  Indeed, the study by Gupta et al. 
(38) found that 9 out of 10 participants were unable to instil their drops correctly 
and Robin et al. (36) suggested that 60% of experienced glaucoma participants 
were unable to instil the correct number of eye drops when observed.  This is 
an additional problem, which is virtually unavoidable at present.   
 
The mean adherence rate for the group calculated by the TDA was slightly 
higher than the findings of previous studies using the TDA.  (Okeke et al., 71% 
(70) and Ajit et al., 80% (34), both over a 3 month period).  The lack of 
agreement with the TDA adherence rate and participant self-report of 
adherence is consistent with previous studies and revealed that participant 
reported non-adherence was below that of the TDA in the majority of cases (34, 
70).  Self-report of adherence is said to be unreliable since patients tend to 
overestimate adherence (86).  The reasons why patients tend to over report 
adherence are thought to be due to participants feeling uneasy about admitting 
non-adherence, or simply being unable to report a missed dose (77).  If non-
adherence is due to forgetfulness, a forgotten dose is unlikely to be 
remembered for reporting purposes.  Thus to reduce memory errors, the length 
of recall period should be minimal.  This study asked participants to recall 
frequency of missed doses over the past month.  A future study should use a 
one week recall period as suggested by Svarstad et al. (77).    
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No literature has been identified that discusses over-reporting of non-adherent 
behaviour and therefore, it is of interest that the present study found over-
reporting of non-adherence using the MMAS Questionnaire.  The MMAS 
Questionnaire is based on phraseology of the questioning bearing positive 
answers, since healthcare providers usually phrase their questions in such a 
way that the answer they want to hear is “yes” (the concept of „leading 
questions‟).  The MMAS measure has been shown to have 69% accuracy but 
only 44% sensitivity (53).  However, MMAS has been linked to positive clinical 
outcomes in hypertension studies.  The possible lack of sensitivity when used in 
the present pilot study may be due to a number of reasons.  The participants in 
Morisky‟s cohort (53) had previously been on blood pressure treatment for an 
average of 6 years whereas 50% of our study population were newly prescribed 
patients.  Furthermore, the wording of the questions were adapted for the use of 
eye drops and referred to eyes rather than asking patients to report on more 
general feelings  and may have contributed to the anomaly.  However, it is 
known that treatment does not aid any symptoms of glaucoma; in fact, the 
preservative within the drop itself, a subsidiary ingredient, may make the eye 
feel more dry and uncomfortable, whilst the positive IOP-lowering effect of the 
drop remains unnoticed.  Thus, it may be that the MMAS questionnaire was not 
a suitable measure of adherence for patients with glaucoma and OH, such as 
those involved in the present study. 
 
It was of interest that some sections of the questionnaire were not completed by 
participants.  The FMD uses a direct questioning of possible non-adherence 
(i.e. „how many times do you miss a dose‟), whereas the MMAS seeks to 
acknowledge attitudes towards adherence behaviour.  Thus, the approach of 
direct questioning of non-adherence could have caused some participants to 
omit this question, in order to conceal the adverse information about themselves 
(87).  These reporting errors suggest that questions may need to be worded 
more carefully to reduce the threat and embarrassment experienced by patients 
who want to make a good impression.  Despite guaranteeing anonymity and 
allowing completion at home, to help participants feel at liberty to report non-
adherence in the present study, it is not possible to determine exactly why these 
parts of the questionnaire where not completed, but if inferred that those 
participants who failed to complete these sections of the questionnaire had not 
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done so due to the potential embarrassment of reporting non-adherence, a 
greater level of association between self-report and TDA adherence scores may 
have been reported.  
 
It is likely that the two questionnaires used in the present study did not have the 
required sensitivity to detect non-adherence, particularly as there was no 
agreement between the measures, rather than the fault lying with the TDA over 
reporting non-adherence.  However, the comparison of self-reported non-
adherence using MMAS before and after monitoring suggested that use of the 
TDA did not affect patient medication taking behaviour.  However, it is 
suggested that a longer period between reporting the initial and final self-report 
of adherence should be used in future studies, since in the present study the 
period of monitoring was shown to have a negative effect on adherence.  
 
Svarstad et al. suggest that multiple self-report tools are needed to detect all the 
different types of non-adherence.  The more minor, sporadic dosing errors are 
more difficult to detect as they are unintentional and thus often erratic when 
compared to repeated dosage errors which stem from intentional behaviour 
traits (77).  The type of observed adherence is an important factor in 
understanding patient behaviour and adds complexity in interpreting results that 
can be useful for clinical use.  A recent study by Ajit et al. (34) developed the 
concept of graphically presenting inter-dose intervals of adherence data.  Ajit et 
al. used this data in order to categorise types of adherence behaviour patterns 
that may be useful for clinical management of patient adherence.  Although 
there was only a small sample size (n=37) they concluded that the TDA 
provided valuable data, which could be used to show the patterns of adherence 
to therapy with travoprost.  Development of a similar computer programme used 
by Ajit et al. should be explored in order to compare the adherence 
categorisations suggested from their study results with a larger cohort.   
  
The lack of association between simple demographic characteristic and 
adherence had been commonly cited (23, 59, 62, 88-90) and is further 
reinforced by the findings of this study.  The only significant predictor of 
adherence was monitoring period.  As the first reported study of this duration 
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and size there, is limited scope for comparison however, the smaller study 
conducted by Ajit et al. (34) reported similar findings.   
 
Previous studies have shown that there is a significant association with 
knowledge about glaucoma and adherence (59, 62, 89, 90).  The present study 
looked at the effect of SIMS rather than knowledge of glaucoma.  It has been 
recognised that provision of information about medication enables patients to 
understand the risks and benefits and their appropriate use (80).  Although it 
was not statistically significant, the present study showed that greater 
adherence correlated with greater satisfaction with information about 
medication.  Participants desired greater information regarding action and 
usage of travoprost, particularly how long travoprost takes to act and how to 
know that it is working. 
  
However, this study was not evidencing an educational intervention and thus 
little variation in satisfaction was expected and therefore significant associations 
with adherence unlikely to be identified.  The results of the present study 
suggest that use of the SIMS questionnaire in any future adherence intervention 
study is acceptable to patients and feasible.  
 
 Ajit et al. found in those completing 75 days of monitoring, the mean average 
adherence rate was 96% in the first 10 days of monitoring, reducing to and 
remaining at 86% after 30 days (34).  The behaviour of a sample population in 
any study could be influenced by participation alone; a participant may become 
more interested in their disease and ask more questions than they would 
normally do (the Hawthorne effect) (58).  Participants of adherence studies may 
adopt a different medication taking behaviour with the knowledge that they are 
being assessed.  However, it is thought that the Hawthorne effect subsides with 
time and that patients are unable to keep up this simulated behaviour for long 
periods with a tendency to revert to habitual behaviour after a certain period of 
time (56).  The latter effect may be the reason for the altered adherence rate 
seen after 100 days of monitoring in the present study.  Reardon et al. found 
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that persistence with glaucoma treatment significantly reduced after one year 
for newly prescribed patients (91).  Thus, the period of monitoring is an 
important aspect in the design of adherence studies; the longer the study, the 
more normal characteristic medication-taking behaviour will become evident as 
the Hawthorne effect diminishes.  Future adherence studies should consider 
longevity in order to study more naturalistic medication-taking behaviour where 
possible.  
 
Lowering IOP to reduce or halt the progression of glaucomatous disease is the 
only accepted intervention available to clinicians.  Topical medication (eye 
drops) used to reduce IOP offers an effective treatment and remains the most 
commonly used first line treatment option for patients with glaucoma or OH 
requiring therapy.  If the eye drop regimen were adhered to, a reduction in IOP 
would be expected on repeat measurement.  However, the percentage 
decrease would be different for each individual; dependent upon the type of 
presenting glaucoma (i.e. high or normal pressure glaucoma), efficacy of the 
particular class of eye drop used (e.g. prostaglandin or beta-blocker) and the 
response shown by each individual.  Measuring the level of IOP to confirm a 
reduction in IOP is standard practice and it would, therefore, seem logical that a 
reduced level of IOP would correlate with adherence.  However, the results of 
the present study found no significant difference in mean IOP between the 
adherent and non-adherent group, and no association between magnitude of 
adherence and reduction in IOP between untreated and treated IOP.  Although 
there should be a relationship a priori between IOP and adherence this has not 
yet been identified in previous research (23) apart from in the study by Konstas 
et al. (35).  Konstas et al. found that their non-adherent group of patients had a 
significantly higher mean IOP than their non-adherent study group.  However, 
their study population consisted of 48% participants with pseudoexfoliation 
glaucoma, a type of glaucoma known to present with higher IOP and with 
greater fluctuations in IOP over a 24 hour period than patients with POAG. 
 
It is clear that individual differences and the type of glaucoma will add to the 
„noisiness‟ of the data when trying to correlate adherence with reduction in IOP.  
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Thus, to eliminate „noise‟ from the data, it would be beneficial to identify the type 
of glaucoma and presenting IOP (and its fluctuation) for each participant, 
particularly as ocular hypotensive therapy not only aims to reduce IOP, but also 
reduces diurnal fluctuation of IOP.   
 
Another factor introducing „noise‟ to the data is the time of day that the IOP is 
measured.  It has been suggested that, since IOP has a diurnal variance, 
participants‟ IOP should be measured at the same time point on repeat 
recordings.  However, there is evidence that the diurnal variation (at least in 
normal eyes) has different patterns from day to day (92) thus adding to the 
difficulty in utilising „random‟ IOP measurements as a measure of adherence.  In 
the study published by Konstas et al. (35), instead of calculating the difference 
in IOP between presenting untreated IOP and the follow-up treated IOP, the 
authors simply measured the treated IOP and calculated the mean IOP level for 
the adherent group and the non-adherent group.   
 
It is also known that, for reasons yet to be fully explained, that ocular 
hypotensive medications have a variable degree of effect in individual eyes, a 
proportion of patients being complete non-responders. Poor responders may, of 
course, be very adherent with their medication, but measuring IOP will not offer 
a useful method to determine the level of adherence for such individuals.  It is 
common that patients showing an apparent poor response to initial therapy will 
be offered a different class of ocular hypotensive, until a medication or 
combination of medications is found to be effective.  The inclusion of patients 
known to have a poor response to treatment when attempting to analyse for a 
correlation between adherence and reduction in IOP will produce rogue data.  In 
real life, the situation is compounded by the fact that non-responders to topical 
medication fall into a number of groups including non-adherers, true non-
responders and those whose presenting IOP was at a trough level in their 
diurnal curve and the treated follow-up IOP at a peak level, making the apparent 
reduction appear small.  
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The recommendations for future studies to examine the role of IOP and 
adherence would follow these guidelines:  
 Group patients according to  
1. diagnosis: e.g. POAG/NTG/Pseudoexfoliation glaucoma  
2. Presenting level of IOP (i.e. high and normal) 
 Only use patients where drop efficacy has been established 
 
However, after establishing these guidelines, it must still be taken into account 
that patient dosing soon before the IOP measurement will have the most crucial 
impact on the level of IOP.  An individual could, for example, be adherent in the 
period leading up to assessment, but not adherent and persistent throughout 
the whole follow-up period.  With respect to travoprost (ideally used the evening 
before a clinic visit) if a dose is missed on the day prior to assessment it is likely 
that the IOP will be higher even if the patient has remained 100% adherent for 
the rest of the monitoring period.  Conversely, the poorly persistent patient 
would have a low IOP if they did administer a dose the night before the clinic 
visit.  The very fact that a patient is due for a clinic visit is in itself a significant 
reminder to the patient that a drop must be taken the night before.  To examine 
the existence of this phenomenon further, the patterns of dosing frequency 
using the TDA data could be used to elicit if a correlation existed between 
increased adherence around the time of follow-up clinic appointments.  
 
An alternative method, would be to measure patients‟ IOP controlled days within 
a given time period, as opposed to using single IOP readings from single clinic 
visits.  This would mean taking an IOP reading every day, perhaps at the same 
time, in order to establish if the IOP were to be at target.  This would be more 
accurate, but logistically less practical, if using the gold standard Goldmann 
tonometry test that requires topical anaesthetic and an experienced clinician 
(18).  In some chronic conditions, such as diabetes and hypertension, patients 
have access to self-assessment equipment such as glucose and blood pressure 
monitors, thus helping patients to have better autonomy with regards to the 
management of their condition.  However, IOP self-measuring devices such as 
   
97 
 
the ICARE® are expensive and still difficult to operate upon oneself in order to 
guarantee accurate results.  Thus, at present, patient self-regulation of IOP is 
not a realistic option and may often leave the patient, who would like to be more 
involved the management of their glaucoma, unable to do so.  However, there is 
potential for researchers to use a device such as ICARE® to obtain measures of 
IOP controlled days if patients were trained to use such devices themselves. 
 
The technique of self-monitoring of IOP would be particularly useful for patients 
where fluctuation of IOP is thought to be significant.  Adherence to medication 
would be assumed for these patients were IOP to remain at a constant level 
without significant diurnal peaks and troughs.  For partially adherent patients, 
the starting and stopping of ocular hypotensives in itself is thought to have the 
potential to cause greater harm because the fluctuation of IOP would be 
accentuated by periods of no therapy and unnecessary IOP peaks.  Controlled 
IOP days is thus a better measure of clinical outcome than a measure of IOP at 
one specific time point within the day.  For high pressure glaucoma patients, a 
better measure of clinical outcome would be to record if the IOP lowering 
treatment has enabled the patient to reach their target IOP of 30% reduction of 
IOP from the baseline measure on multiple occasions.  
 
The ultimate device to aid the assessment of IOP control, with the added 
advantage of offering the potential to assess adherence with respect to IOP, 
would be a system that would enable continuous IOP monitoring.  At present, 
continuous IOP monitoring devices remain experimental, but in the future these 
may become extremely useful for routine clinical practice and in research (93). 
 
The complexity of using IOP as a measure of adherence calls into question its 
current feasibility, particularly when other measures of adherence appear both 
more practicable and reliable.  At present, clinicians must accept that one good 
IOP measure within the target range reading does not constitute good 
adherence by any means, nor does a higher than expected reading equate to 
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poor adherence - drop efficacy, type of glaucoma and frequency of missed 
doses must all be considered.  
 
 
4.1 Conclusions 
Since adherence has been shown to be affected by the period of monitoring, 
future studies should aim to measure adherence for more than 100 days to 
establish if adherence is maintained long term.  In addition, the level of 
adherence needs to be measured against clinical outcomes expected for 
glaucoma patients.  Presently, the 80% adherence goal is based on 
recommendations for the therapeutic control of hypertension, rather than for 
glaucoma itself.  As reported, robust short-term measures of clinical outcomes 
are problematic to achieve and thus longer-term studies of adherence to 
glaucoma medication and its affect on measurable clinical outcomes such as 
optic nerve damage and visual field loss are required.  
 
This study has provided preliminary evidence that use of the TDA does not 
significantly alter patient eye drop use behaviour.  The TDA, despite its reported 
limitations, can provide valuable data regarding patient adherence to glaucoma 
medication.  Where previous studies have failed to use effective methodologies, 
the TDA offers an objective adherence measure for future studies.  The TDA 
offers the additional benefit that it records the exact patient dosing times.  It 
therefore offers clinicians and researchers an exceptional tool for gathering 
adherence behaviour patterns rather than just being limited to percentage 
adherence data.  Thus, the TDA may be useful as an aid for clinical 
management decisions, particularly if the data can be represented in a 
meaningful way, such as a graphical representation of patient adherence.  
 
The educational needs of glaucoma patients in relation to adherence to eye 
drops still remains poorly understood.  Using the TDA for glaucoma educational 
intervention studies has the potential to provide a greater understanding of 
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patient drop-taking behaviour and adherence enabling healthcare practitioners 
to focus information and educational support to glaucoma patients.  
Furthermore, it may help to identify predictors of poor adherence, enabling 
identification of vulnerable individuals for additional support. 
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Travalert Pilot Study: Patient discussion template 
 
Below are the 3 main areas that will be discussed with the patient in order to 
determine the suitability of the trial design from the patient‟s perspective.  For 2 
questions, additional prompts have been included indicated by the sub 
categories. 
1. Approximately how long did it take you to complete the questionnaire? 
 
2. Did you encounter any difficulties or problems with completing the 
questionnaire? 
a. Any questions difficult to answer 
b. Were you unsure about what information questions were 
requesting 
 
3. Did you experience any problems using the Travalert Device? 
a. Was it convenient? 
b. Was it easy to use? 
 
